



PCT/EP 03/12161

21 JAN 2004



INVESTOR IN PEOPLE

The Patent Office
Concept House
Cardiff Road
Newport
South Wales
NP10 8QQ

REC'D 04 FEB 2004

WIPO

PCT

I, the undersigned, being an officer duly authorised in accordance with Section 74(1) and (4) of the Deregulation & Contracting Out Act 1994, to sign and issue certificates on behalf of the Comptroller-General, hereby certify that annexed hereto is a true copy of the documents as originally filed in connection with the patent application identified therein.

In accordance with the Patents (Companies Re-registration) Rules 1982, if a company named in this certificate and any accompanying documents has re-registered under the Companies Act 1980 with the same name as that with which it was registered immediately before re-registration save for the substitution as, or inclusion as, the last part of the name of the words "public limited company" or their equivalents in Welsh, references to the name of the company in this certificate and any accompanying documents shall be treated as references to the name with which it is so re-registered.

In accordance with the rules, the words "public limited company" may be replaced by p.l.c., plc, P.L.C. or PLC.

Re-registration under the Companies Act does not constitute a new legal entity but merely subjects the company to certain additional company law rules.

Signed

Stephen Hordley

Dated

24 October 2003

PRIORITY DOCUMENT

SUBMITTED OR TRANSMITTED IN
COMPLIANCE WITH RULE 17.1(a) OR (b)

Patents Form 1/77



ents Act 1977
(rule 16)

The
Patent
Office

04HUV02 E76050 -4 001030
P01/7700 0.00-0225540.4

1/77

Request for grant of a patent

(See the notes on the back of this form. You can also get an explanatory leaflet from the Patent Office to help you fill in this form)

The Patent Office
Cardiff Road
Newport
Gwent NP9 1RH

1. Your Reference	JAF/PG5019	0225540.4	01 NOV 2002
2. Patent application number <i>(The Patent office will fill in this part)</i>			
3. Full name, address and postcode of the or of each applicant <i>(underline all surnames)</i>	GLAXO GROUP LIMITED GLAXO WELLCOME HOUSE BERKELEY AVENUE GREENFORD MIDDLESEX UB6 0NN GB		
Patents ADP number <i>(if you know it)</i>	473587003		
If the applicant is a corporate body, give the country/state of its corporation	GB		
4 Title of the invention	MEDICINAL COMPOUNDS		
5 Name of your agent <i>(if you know one)</i>	JULIA A FLORENCE		
"Address for service" in the United Kingdom to which all correspondence should be sent <i>(including the postcode)</i>	GLAXOSMITHKLINE CORPORATE INTELLECTUAL PROPERTY 980 GREAT WEST ROAD BRENTFORD, MIDDLESEX TW8 9GS, GB		
Patents ADP number <i>(if you know it)</i>	80782555006		
6. If you are declaring priority from one or more earlier patent applications, give the country and date of filing of the or of each of these earlier applications and <i>(if you know it)</i> the or each application number	Country	Priority application number <i>(if you know it)</i>	Date of Filing <i>(day / month / year)</i>
7. If this application is divided or otherwise derived from an earlier UK application, give the number and the filing date of the earlier application	Number of earlier application		Date of filing <i>(day / month / year)</i>
8. Is a statement of inventorship and of right to grant a patent required in support of this request? <i>(Answer yes if:</i>	YES		
<i>a) any applicant named in part 3 is not an inventor, or</i>			
<i>b) there is an inventor who is not named as an applicant, or</i>			
<i>c) any named applicant is a corporate body.</i>			
<i>See note (d))</i>			
9. Enter the number of sheets for any of the			

Patents Form 1/77

following items you are filing with this form.
Do count copies of the same document

Description	77 /	CL
Claim(s)	8 /	
Abstract	1 /	
Drawing(s)	-	

10. If you are also filing any of the following,
state how many against each item

Priority Documents

Translations of priority documents

Statement of inventorship and right
to grant of a patent (*Patents Form 7/77*)

Request for preliminary examination
and search (*Patent Form 9/77*)

Request for substantive examination
(*Patent Form 10/77*)

Any other documents
(please specify)

11.

I/We request the grant of a patent on the basis of this application

Signature JULIA A FLORENCE 1 November 2002
Julia Florence
AGENT FOR THE APPLICANTS

12. Name and daytime telephone number of
person to contact in the United Kingdom

LESLEY WELLS

01438 76 8599

Warning

After an application for a patent has been filed, the Comptroller of the Patent Office will consider whether publication of communication of the invention should be prohibited or restricted under Section 22 of the Patents Act 1977. You will be informed if it is necessary to prohibit or restrict your invention in this way. Furthermore, if you live in the United Kingdom, Section 23 of the patent Act 1977 stops you from applying for a patent abroad without first getting written permission from the Patent Office unless an application has been filed at least 6 weeks beforehand in the United Kingdom for a patent for the same invention and either no direction prohibiting publication or communication has been given, or any such direction has been received

a) **Notes**

If you need help to fill in this form or you have any questions, please contact the Patent Office on 0645 500505.

b) Write your answers in capital letters using black ink or you may type them.

c) If there is not enough space for all the relevant details on any part of this form, please continue on a separate sheet of paper and write "see continuation sheet" in the relevant part(s). Any continuation sheet should be attached to this form

If you have answered "Yes" Patents Form 7/77 will need to be filed.

d) Once you have filled in the form you must remember to sign and date it.

e) For details of the fee and ways to pay please contact the Patent Office.

Medicinal Compounds


5 The present invention is concerned with phenethanolamine derivatives, processes for their preparation, compositions containing them and their use in medicine, particularly in the prophylaxis and treatment of respiratory diseases.

10 Certain phenethanolamine compounds are known in the art as having selective stimulant action at β_2 -adrenoreceptors and therefore having utility in the treatment of bronchial asthma and related disorders. Thus GB 2 140 800 describes phenethanolamine compounds including 4-hydroxy- α^1 -[[[6-(4-phenylbutoxy)hexyl]amino]methyl]-1,3-benzenedimethanol 1-hydroxy-2-naphthalenecarboxylate (salmeterol xinafoate) which is now used clinically in the treatment of such medical conditions.

15 Although salmeterol and the other commercially available β_2 -adrenoreceptor agonists are effective bronchodilators, the maximum duration of action is 12 hours, hence twice daily dosing is often required. There is therefore a clinical need for compounds having potent and selective stimulant action at β_2 -adrenoreceptors and having an advantageous profile of action.

20

According to the present invention, there is provided a compound of formula (I)



25 or a salt, solvate, or physiologically functional derivative thereof, wherein:

m is an integer of from 2 to 8;

n is an integer of from 3 to 11, preferably from 3 to 7;

with the proviso that m + n is 5 to 19, preferably from 5 to 12;

30

R^1 is $-XNR^6C(O)NR^7R^8$, wherein

X is selected from $-(CH_2)_p-$ and C_{2-6} alkenylene;


5 R^6 and R^8 are independently selected from hydrogen, C_{1-6} alkyl and C_{3-7} cycloalkyl;

10 R^7 is selected from hydrogen, C_{1-6} alkyl, C_{3-7} cycloalkyl, $-C(O)R^9$, phenyl, naphthyl, hetaryl, and phenyl(C_{1-4} alkyl)- and R^7 is optionally substituted by 1 or 2 groups independently selected from halo, hydroxy, C_{1-6} alkyl, C_{1-6} haloalkyl, C_{1-6} alkoxy, $-NHC(O)(C_{1-6}$ alkyl), $-SO_2(C_{1-6}$ alkyl), $-SO_2$ (phenyl), $-CO_2H$, and $-CO_2(C_{1-4}$ alkyl);

15 R^9 is selected from C_{1-6} alkyl, C_{3-7} cycloalkyl, $-CO_2H$, $CO_2(C_{1-4}$ alkyl), phenyl, naphthyl, hetaryl, and phenyl(C_{1-4} alkyl)- and R^9 is optionally substituted by 1 or 2 groups independently selected from halo, C_{1-6} alkyl, C_{1-6} haloalkyl, C_{1-6} alkoxy, $-NHC(O)(C_{1-6}$ alkyl), $-SO_2(C_{1-6}$ alkyl), $-SO_2$ (phenyl), $-CO_2H$, and $-CO_2(C_{1-4}$ alkyl); and

p is an integer from 0 to 6, preferably from 0 to 4;

20 or R^1 is cyclised such that R^8 forms a bond with the phenyl ring to which R^1 is attached, via the ring carbon atom adjacent to R^1 , so as to form a moiety of the formula:



R^2 is selected from hydrogen, C_{1-6} alkyl, C_{1-6} alkoxy, phenyl, halo, and C_{1-6} haloalkyl;

25

R^3 is selected from hydrogen, hydroxy, C_{1-6} alkyl, halo, C_{1-6} alkoxy, phenyl, C_{1-6} haloalkyl, and $-SO_2NR^{10}R^{11}$;


wherein R¹⁰ and R¹¹ are independently selected from hydrogen, C₁₋₆alkyl, C₃₋₆cycloalkyl, phenyl, and phenyl (C₁₋₄alkyl), or R¹⁰ and R¹¹, together with the nitrogen to which they are bonded, form a 5-, 6-, or 7-membered nitrogen containing ring;

5 and R¹⁰ and R¹¹ are each optionally substituted by one or two groups selected from halo, C₁₋₆alkyl, and C₁₋₆haloalkyl;


R⁴ and R⁵ are independently selected from hydrogen and C₁₋₄alkyl with the proviso that the total number of carbon atoms in R⁴ and R⁵ is not more than 4;

10


and Ar¹ is a group selected from



(a)




(b)



(c)

and



(d)

15 wherein R¹² represents halogen, -(CH₂)_qOR¹⁶, -NR¹⁶C(O)R¹⁷, -NR¹⁶SO₂R¹⁷, -SO₂NR¹⁶R¹⁷, -NR¹⁶R¹⁷, -OC(O)R¹⁸ or OC(O)NR¹⁶R¹⁷, and R¹³ represents hydrogen, halogen or C₁₋₄ alkyl;

or R¹² represents -NHR¹⁹ and R¹³ and -NHR¹⁹ together form a 5- or 6- membered heterocyclic ring;

R¹⁴ represents hydrogen, halogen, -OR¹⁸ or -NR¹⁶R¹⁷;

5 R¹⁵ represents hydrogen, halogen, haloC₁₋₄ alkyl, -OR¹⁶, -NR¹⁶R¹⁷, -OC(O)R¹⁸ or OC(O)NR¹⁶R¹⁷;

10 R¹⁶ and R¹⁷ each independently represents hydrogen or C₁₋₄ alkyl, or in the groups -NR¹⁶R¹⁷, -SO₂NR¹⁶R¹⁷ and -OC(O)NR¹⁶R¹⁷, R¹⁶ and R¹⁷ independently represent hydrogen or C₁₋₄ alkyl or together with the nitrogen atom to which they are attached form a 5-, 6- or 7- membered nitrogen-containing ring,

15 R¹⁸ represents an aryl (eg phenyl or naphthyl) group which may be unsubstituted or substituted by one or more substituents selected from halogen, C₁₋₄ alkyl, hydroxy, C₁₋₄ alkoxy or halo C₁₋₄ alkyl; and

q is zero or an integer from 1 to 4;

20 with the provisos that:

- a) when Ar¹ denotes a group (i) as defined herinafter, R², R³, R⁴, R⁵, and R⁶ each denote hydrogen, m is 5, n is 2, and X denotes -(CH₂)_p- and is in the para position relative to the -O-(CH₂)_n- link, and p is 0, then R⁷ and R⁸ are not both hydrogen; and
- 25 b) when Ar¹ denotes a group (i) as defined hereinafter, R², R³, R⁴, R⁵, and R⁶ each denote hydrogen, m is 5, n is 4, and X denotes -(CH₂)_p- and is in the para position relative to the -O-(CH₂)_n- link, and p is 0, then R⁷ and R⁸ are not both methyl;

30 In the definition of R³, the term "5-, 6-, or 7- membered nitrogen containing ring" means a 5-, 6-, or 7- membered saturated or unsaturated ring which includes a nitrogen atom and optionally 1 or 2 other heteroatoms independently selected from nitrogen, sulphur, and oxygen. Suitable examples of such a ring include piperidinyl, morpholinyl, and piperazinyl.

In the definition of R⁷, the term "hetaryl" means a 5- or 6-membered heteroaromatic ring, such as thienyl, pyrimidine, or pyridyl.

In the definition of X, the term alkenylene includes both *cis* and *trans* structures.

5 Suitable examples of alkenylene groups include -CH=CH-.

In the compounds of formula (I) R¹ is preferably as defined hereinafter. R² is preferably hydrogen. R³ is preferably hydrogen or C₁₋₆ alkyl.

10 In the compounds of formula (I), R⁴ and R⁵ are preferably independently selected from hydrogen and methyl, more preferably R⁴ and R⁵ are both hydrogen.

15 In the compounds of formula (I), m is suitably 3, 4 or 5, and preferably m is 5, and n is suitably 3 to 6 and preferably n is 3 or 4. More preferably n is 5 or 6 and n is 3 or 4 such that the sum of m + n is 8, 9 or 10, most preferably 9.

20 In the compounds of formula (I) the group Ar¹ is preferably selected from groups (a) and (b) above. In said groups (a) and (b), when R¹² represents halogen this is preferably chlorine or fluorine. R¹⁶ and R¹⁷ preferably each independently represent hydrogen or methyl. R¹⁸ preferably represents substituted phenyl. The integer n preferably represents zero or 1. Thus for example -(CH₂)_nOR¹⁶ preferably represents OH or -CH₂OH;

NR¹⁶C(O)R¹⁷ preferably represents -NHC(O)H;

-SO₂NR¹⁶R¹⁷ preferably represents -SO₂NH₂ or SO₂NHCH₃;

25 -NR¹⁶SO₂R¹⁷ preferably represents NHSO₂CH₃;

NR¹⁶R¹⁷ preferably represents -NH₂;

-OC(O)R¹⁸ preferably represents substituted benzyloxy eg. OC(O)-C₆H₄-(p-CH₃); and

-OC(O)N R¹⁶ R¹⁷ preferably represents OC(O)N(CH₃)₂.

30 When R¹² represents NHR¹⁹ and together with R¹³ forms a 5- or 6- membered heterocyclic ring -NHR¹⁹-R¹³- preferably represents a group:


-NH-CO-R²⁰ where R²⁰ is an alkylene, alkenylene or alkenyloxy group;

-NH-SO₂R²¹ where R²¹ is an alkenyloxy group;


-NH-R²²- where R²² is an alkylene or alkenylene group optionally substituted by COOR²³
 where R²³ is C₁₋₄ alkyl; or
 -NH-CO-CH- or NH-CO-S- wherein said alkylene, and alkenylene groups and moieties
 contain 1 or 2 carbon atoms.

5


Particularly preferred groups (a) and (b) may be selected from the following groups (i) to (xxi):




(i)




(ii)




(iii)




(iv)




(v)




(vi)




(vii)




(viii)




(ix)



(x)




(xi)




(xii)


10




(xiii)




(xiv)



(xv)



(xvi)




(xvii)




(xviii)



(xix)




(xx)



(xxi)


wherein the dotted line in (xvi) and (xix) denotes an optional double bond.

According to a preferred aspect of the invention, there is provided a compound of formula (Ia)



- 5 or a salt, solvate, or physiologically functional derivative thereof, wherein R¹ and R³ are
as defined above for formula (I).

10 According to a further preferred aspect of the invention, there is provided a compound
of formula (Ib)



- 15 or a salt, solvate, or physiologically functional derivative thereof, wherein R¹ and R³ are
as defined above for formula (I).

In the compounds of formulae (I), (Ia) and (Ib), the group R¹ is preferably attached to the
meta-position relative to the -O-(CH₂)_n-, -O-(CH₂)₄- or -O-(CH₂)₃- link respectively.

- 20 In the compounds of formulae (I), (Ia) and (Ib), the group R¹ is preferably
-(CH₂)_p-NHC(O)NHR⁷ and R⁷ is preferably hydrogen.

In the compounds of formulae (I), (Ia) and (Ib), p is preferably 0, 1, or 2.

- 25 In the compounds of formulae (I), (Ia) and (Ib), R³ is preferably hydrogen or
C₁₋₆alkyl, eg. methyl

It is to be understood that the present invention covers all combinations of particular and preferred groups described hereinabove.

5 The compounds of formulae (I), (Ia) and (Ib) include an asymmetric centre, namely the carbon atom of the



group. The present invention includes both (S) and (R) enantiomers either in substantially pure form or admixed in any proportions.

10

Similarly, where R⁴ and R⁵ are different groups, the carbon atom to which they are attached is an asymmetric centre and the present invention includes both (S) and (R) enantiomers at this centre either in substantially pure form or admixed in any proportions.

15

Thus the compounds of formulae (I), (Ia) and (Ib) include all enantiomers and diastereoisomers as well as mixtures thereof in any proportions.

Preferred compounds of the invention include:

20

N-(4-fluorophenyl)-N'-[3-(4-[(6-((2R)-2-hydroxy-2-[4-hydroxy-3-(hydroxymethyl)phenyl]ethyl)amino)hexyl]oxy]butyl]phenyl]urea;
 N-(2,6-dichlorophenyl)-N'-[3-(4-[(6-((2R)-2-hydroxy-2-[4-hydroxy-3-(hydroxymethyl)phenyl]ethyl)amino)hexyl]oxy]butyl]phenyl]urea acetate;
 25 N-[3-(4-[(6-((2R)-2-hydroxy-2-[4-hydroxy-3-(hydroxymethyl)phenyl]ethyl)amino)hexyl]oxy]butyl]phenyl]-N'-(4-methylphenyl)urea;
 ([[3-(4-[(6-((2R)-2-hydroxy-2-[4-hydroxy-3-(hydroxymethyl)phenyl]ethyl)amino)hexyl]oxy]butyl]anilino]carbonyl)amino)acetic acid;
 N-[3-(4-[(6-((2R)-2-hydroxy-2-[4-hydroxy-3-(hydroxymethyl)phenyl]ethyl)amino)hexyl]oxy]butyl]phenyl]-N'-[3-(trifluoromethyl)phenyl]urea;
 30 N-(2,6-dimethylphenyl)-N'-[3-(4-[(6-((2R)-2-hydroxy-2-[4-hydroxy-3-(hydroxymethyl)phenyl]ethyl)amino)hexyl]oxy]butyl]phenyl]urea;
 3-(4-[(6-((2R)-2-hydroxy-2-[4-hydroxy-3-(hydroxymethyl)phenyl]ethyl)amino)hexyl]oxy]butyl)phenyl]-N'-phenylurea;

- N-Ethyl-N'-[3-(4-[{6-((2R)-2-hydroxy-2-[4-hydroxy-3-(hydroxymethyl)phenyl]ethyl}amino)hexyl]oxy}butyl]phenyl]urea;
Ethyl ([{3-(4-[{6-((2R)-2-hydroxy-2-[4-hydroxy-3-(hydroxymethyl)phenyl]ethyl}amino)hexyl]oxy}butyl]anilino]carbonyl)amino)acetate;
- 5 N-cyclohexyl-N'-(3-(4-[{6-((2R)-2-hydroxy-2-[4-hydroxy-3-(hydroxymethyl)phenyl]ethyl}amino)hexyl]oxy}butyl]phenyl]urea;
N-[4-(4-[{6-((2R)-2-hydroxy-2-[4-hydroxy-3-(hydroxymethyl)phenyl]ethyl}amino)hexyl]oxy}butyl]phenyl]-N'-phenylurea;
N-Ethyl-N'-[4-(4-[{6-((2R)-2-hydroxy-2-[4-hydroxy-3-(hydroxymethyl)phenyl]ethyl}amino)hexyl]oxy}butyl]phenyl]urea;
- 10 10 N-[3-(4-[{6-((2R)-2-hydroxy-2-[4-hydroxy-3-(hydroxymethyl)phenyl]ethyl}amino)hexyl]oxy}butyl]phenyl]-N'-pyridin-3-ylurea;
N-[3-(4-[{6-((2R)-2-hydroxy-2-[4-hydroxy-3-(hydroxymethyl)phenyl]ethyl}amino)hexyl]oxy}butyl]phenyl]-N'-pyrimidin-4-ylurea;
15 N-[3,5-bis(trifluoromethyl)phenyl]-N'-[3-(4-[{6-((2R)-2-hydroxy-2-[4-hydroxy-3-(hydroxymethyl)phenyl]ethyl}amino)hexyl]oxy}butyl]phenyl]urea;
N-cyclohexyl-N'-(3-(4-[{6-((2R)-2-hydroxy-2-[4-hydroxy-3-(hydroxymethyl)phenyl]ethyl}amino)hexyl]oxy}butyl)benzyl]urea;
N-Ethyl-N'-[3-(4-[{6-((2R)-2-hydroxy-2-[4-hydroxy-3-(hydroxymethyl)phenyl]ethyl}amino)hexyl]oxy}butyl]benzyl]urea;
- 20 20 N-[3-(4-[{6-((2R)-2-hydroxy-2-[4-hydroxy-3-(hydroxymethyl)phenyl]ethyl}amino)hexyl]oxy}butyl]benzyl]urea;
N-(4-fluorophenyl)-N'-[3-(4-[{6-((2R)-2-hydroxy-2-[4-hydroxy-3-(hydroxymethyl)phenyl]ethyl}amino)hexyl]oxy}butyl]benzyl]urea;
25 N-(3-chlorophenyl)-N'-[3-(4-[{6-((2R)-2-hydroxy-2-[4-hydroxy-3-(hydroxymethyl)phenyl]ethyl}amino)hexyl]oxy}butyl]benzyl]urea;
N-benzyl-N'-[3-(4-[{6-((2R)-2-hydroxy-2-[4-hydroxy-3-(hydroxymethyl)phenyl]ethyl}amino)hexyl]oxy}butyl]benzyl]urea;
N-({[2-(4-[{6-((2R)-2-hydroxy-2-[4-hydroxy-3-(hydroxymethyl)phenyl]ethyl}amino)hexyl]oxy}butyl]benzyl]amino)carbonyl)glycine;
- 30 30 N-{2-[3-(4-[{6-((2R)-2-hydroxy-2-[4-hydroxy-3-(hydroxymethyl)phenyl]ethyl}amino)hexyl]oxy}butyl]phenyl]ethyl}-N'-phenylurea;
N-[3-(4-[{6-((2R)-2-hydroxy-2-[4-hydroxy-3-(hydroxymethyl)phenyl]ethyl}amino)hexyl]oxy}butyl]phenyl]urea;

- N-[3-(3-{{(2R)-2-hydroxy-2-[4-hydroxy-3-
(hydroxymethyl)phenyl]ethyl}amino}heptyl]oxy}propyl]phenyl]urea;
N-[3-(5-{{(2R)-2-hydroxy-2-[4-hydroxy-3-
(hydroxymethyl)phenyl]ethyl}amino}pentyl]oxy}pentyl]phenyl]urea;
5 N-[3-(5-{{[6-((2R)-2-hydroxy-2-[4-hydroxy-3-
(hydroxymethyl)phenyl]ethyl}amino)hexyl]oxy}pentyl]phenyl]urea;
N-[3-(4-{{[6-((2R)-2-hydroxy-2-[4-hydroxy-3-
(hydroxymethyl)phenyl]ethyl}amino)hexyl]oxy}butyl)-5-(trifluoromethyl)phenyl]urea;
N-[3-(4-{{[6-((2R)-2-hydroxy-2-[4-hydroxy-3-
10 (hydroxymethyl)phenyl]ethyl}amino)hexyl]oxy}butyl)-5-methylphenyl]urea;
5-(4-{{[6-((2R)-2-hydroxy-2-[4-hydroxy-3-
(hydroxymethyl)phenyl]ethyl}amino)hexyl]oxy}butyl)-1,3-dihydro-2H-benzimidazol-2-
one;
N-Benzoyl-N'-[3-(4-{{[6-((2R)-2-hydroxy-2-[4-hydroxy-3-
15 (hydroxymethyl)phenyl]ethyl}amino)hexyl]oxy}butyl]phenyl]urea;
N-[2-(4-{{[6-((2R)-2-hydroxy-2-[4-hydroxy-3-
(hydroxymethyl)phenyl]ethyl}amino)hexyl]oxy}butyl]phenyl]-N'-phenylurea;
N-[3-(4-{{[6-((2R)-2-hydroxy-2-[4-hydroxy-3-
(hydroxymethyl)phenyl]ethyl}amino)hexyl]oxy}butyl]phenyl]-N'-(3-hydroxyphenyl)urea;
20 {[{[3-(4-{{[6-((2R)-2-hydroxy-2-[4-hydroxy-3-
(hydroxymethyl)phenyl]ethyl}amino)hexyl]oxy}butyl]phenyl]amino}carbonyl]amino}(oxo)
acetic acid;
N-[3-(4-{{[6-((2R)-2-[3-(Formylamino)-4-hydroxyphenyl]-2-
hydroxyethyl]amino)hexyl]oxy}butyl]phenyl]urea;
25 N-[3-(4-{{[6-((2R)-2-[3-(Formylamino)-4-hydroxyphenyl]-2-
hydroxyethyl]amino)hexyl]oxy}butyl]phenyl]-N'-phenylurea;
N-[3-(4-{{[6-((2R)-2-[3-(Formylamino)-4-hydroxyphenyl]-2-
hydroxyethyl]amino)hexyl]oxy}butyl]phenyl]-N'-pyridin-3-ylurea with (2E)-but-2-enedioic
acid (1:1).
30 and salts, solvates, and physiologically functional derivatives thereof.

Particularly preferred compounds of the invention include:

N-[3-(4-{[6-((2R)-2-hydroxy-2-[4-hydroxy-3-(hydroxymethyl)phenyl]ethyl)amino]hexyl}oxy)butyl]phenyl]urea;
3-(4-{[6-((2R)-2-hydroxy-2-[4-hydroxy-3-(hydroxymethyl)phenyl]ethyl)-amino]hexyl}oxy)butyl)phenyl]-N'-phenylurea;

5 N-[3-(4-{[6-((2S)-2-hydroxy-2-[4-hydroxy-3-(hydroxymethyl)phenyl]ethyl)amino]hexyl}oxy)butyl]phenyl]urea;
3-(4-{[6-((2S)-2-hydroxy-2-[4-hydroxy-3-(hydroxymethyl)phenyl]ethyl)-amino]hexyl}oxy)butyl)phenyl]-N'-phenylurea;

10 N-[3-(4-{[6-((2-hydroxy-2-[4-hydroxy-3-(hydroxymethyl)phenyl]ethyl)amino]hexyl}oxy)butyl]phenyl]urea;
3-(4-{[6-((2-hydroxy-2-[4-hydroxy-3-(hydroxymethyl)phenyl]ethyl)-amino]hexyl}oxy)butyl)phenyl]-N'-phenylurea; and
N-[3-(4-{[6-((2R)-2-hydroxy-2-[4-hydroxy-3-(hydroxymethyl)phenyl]ethyl)amino]hexyl}oxy)butyl]-5-methylphenyl]urea;

15 and salts, solvates and physiologically functional equivalents thereof.

20 Salts and solvates of compounds of formulae (I), (Ia) and (Ib) which are suitable for use in medicine are those wherein the counterion or associated solvent is pharmaceutically acceptable. However, salts and solvates having non-pharmaceutically acceptable counterions or associated solvents are within the scope of the present invention, for example, for use as intermediates in the preparation of other compounds of formulae (I), (Ia) and (Ib) and their pharmaceutically acceptable salts, solvates, and physiologically functional derivatives.

25 By the term "physiologically functional derivative" is meant a chemical derivative of a compound of formula (I), (Ia) or (Ib) having the same physiological function as the free compound of formula (I), (Ia) or (Ib), for example, by being convertible in the body thereto. According to the present invention, examples of physiologically functional derivatives include esters.

30 Suitable salts according to the invention include those formed with both organic and inorganic acids or bases. Pharmaceutically acceptable acid addition salts include those formed from hydrochloric, hydrobromic, sulphuric, citric, tartaric, phosphoric, lactic, pyruvic, acetic, trifluoroacetic, triphenylacetic, sulphamic, sulphanilic, succinic, oxalic,

fumaric, maleic, malic, glutamic, aspartic, oxaloacetic, methanesulphonic, ethanesulphonic, arylsulphonic (for example p-toluenesulphonic, benzenesulphonic, naphthalenesulphonic or naphthalenedisulphonic), salicylic, glutaric, gluconic, tricarballylic, cinnamic, substituted cinnamic (for example, methyl, methoxy or halo substituted cinnamic, including 4-methyl and 4-methoxycinnamic acid), ascorbic, oleic, naphthoic, hydroxynaphthoic (for example 1- or 3-hydroxy-2-naphthoic), naphthaleneacrylic (for example naphthalene-2-acrylic), benzoic, 4-methoxybenzoic, 2- or 4-hydroxybenzoic, 4-chlorobenzoic, 4-phenylbenzoic, benzeneacrylic (for example 1,4-benzenediacrylic) and isethionic acids. Pharmaceutically acceptable base salts include ammonium salts, alkali metal salts such as those of sodium and potassium, alkaline earth metal salts such as those of calcium and magnesium and salts with organic bases such as dicyclohexyl amine and N-methyl-D-glucamine.

15 Pharmaceutically acceptable esters of the compounds of formulae (I), (Ia) and (Ib) may have a hydroxyl group converted to a C₁₋₆alkyl, aryl, aryl C₁₋₆ alkyl, or amino acid ester.

As mentioned above, the compounds of formulae (I), (Ia) and (Ib) are selective β₂-adrenoreceptor agonists as demonstrated using functional or reporter gene readout from cell lines transfected with human beta-adrenoreceptors as described below.

20 Compounds according to the present invention also have the potential to combine long duration of effect with rapid onset of action. Furthermore, certain compounds have shown an improved therapeutic index in animal models relative to existing long-acting β₂-agonist bronchodilators. As such, compounds of the invention may be suitable for once-daily administration.

25 Therefore, compounds of formulae (I), (Ia) and (Ib) and their pharmaceutically acceptable salts, solvates, and physiologically functional derivatives have use in the prophylaxis and treatment of clinical conditions for which a selective β₂-adrenoreceptor agonist is indicated. Such conditions include diseases associated with reversible airways obstruction such as asthma, chronic obstructive pulmonary diseases (COPD) (e.g. chronic and wheezy bronchitis; emphysema), respiratory tract infection and upper respiratory tract disease (e.g. rhinitis, including seasonal and allergic rhinitis).

Other conditions which may be treated include premature labour, depression, congestive heart failure, skin diseases (e.g. inflammatory, allergic, psoriatic, and proliferative skin diseases), conditions where lowering peptic acidity is desirable (e.g. peptic and gastric ulceration) and muscle wasting disease.

- 5 Accordingly, the present invention provides a method for the prophylaxis or treatment of a clinical condition in a mammal, such as a human, for which a selective β_2 -adrenoreceptor agonist is indicated, which comprises administration of a therapeutically effective amount of a compound of formula (I), (Ia) or (Ib), or a pharmaceutically acceptable salt, solvate, or physiologically functional derivative thereof. In particular, the present invention provides such a method for the prophylaxis or treatment of a disease associated with reversible airways obstruction such as asthma, chronic obstructive pulmonary disease (COPD), respiratory tract infection or upper respiratory tract disease. In a further aspect the present invention provides such a method for the prophylaxis or treatment of a clinical condition selected from premature labour, depression, congestive heart failure, skin diseases (e.g. inflammatory, allergic, psoriatic, and proliferative skin diseases), conditions where lowering peptic acidity is desirable (e.g. peptic and gastric ulceration) or muscle wasting disease.
- 10 15
- 20 In the alternative, there is also provided a compound of formula (I), (Ia) or (Ib) or a pharmaceutically acceptable salt, solvate, or physiologically functional derivative thereof for use in medical therapy, particularly, for use in the prophylaxis or treatment of a clinical condition in a mammal, such as a human, for which a selective β_2 -adrenoreceptor agonist is indicated. In particular, there is provided a compound of formula (I), (Ia) or (Ib) or a pharmaceutically acceptable salt, solvate, or physiologically functional derivative thereof for the prophylaxis or treatment of a disease associated with reversible airways obstruction such as asthma, chronic obstructive pulmonary disease (COPD), respiratory tract infection or upper respiratory tract disease. In a further aspect, there is provided a compound of formula (I), (Ia) or (Ib) or a
- 25 30
- 35 pharmaceutically acceptable salt, solvate, or physiologically functional derivative thereof for the prophylaxis or treatment of a clinical condition selected from premature labour, depression, congestive heart failure, skin diseases (e.g. inflammatory, allergic, psoriatic, and proliferative skin diseases), conditions where lowering peptic acidity is desirable (e.g. peptic and gastric ulceration) or muscle wasting disease.

The present invention also provides the use of a compound of formula (I), (Ia) or (Ib), or a pharmaceutically acceptable salt, solvate, or physiologically functional derivative thereof in the manufacture of a medicament for the prophylaxis or treatment of a clinical condition for which a selective β_2 -adrenoreceptor agonist is indicated, for example a

5 disease associated with reversible airways obstruction such as asthma, chronic obstructive pulmonary disease (COPD), respiratory tract infection or upper respiratory tract disease. In a further aspect, there is provided a compound of formula (I), (Ia) or (Ib), or a pharmaceutically acceptable salt, solvate, or physiologically functional derivative thereof in the manufacture of a medicament for the prophylaxis or treatment 10 of a clinical condition selected from premature labour, depression, congestive heart failure, skin diseases (e.g. inflammatory, allergic, psoriatic, and proliferative skin diseases), conditions where lowering peptic acidity is desirable (e.g. peptic and gastric ulceration) and muscle wasting disease.

15 The amount of a compound of formula (I), (Ia) or (Ib), or a pharmaceutically acceptable salt, solvate or physiologically functional derivative thereof which is required to achieve a therapeutic effect will, of course, vary with the particular compound, the route of administration, the subject under treatment, and the particular disorder or disease being treated. The compounds of the invention may be administered by inhalation at a dose 20 of from 0.0005mg to 10 mg, preferably 0.005mg to 0.5mg. The dose range for adult humans is generally from 0.0005 mg to 100mg per day and preferably 0.01 mg to 1mg per day.

25 While it is possible for the compound of formula (I), (Ia) or (Ib), or a pharmaceutically acceptable salt, solvate, or physiologically functional derivative thereof to be administered alone, it is preferable to present it as a pharmaceutical formulation.

Accordingly, the present invention further provides a pharmaceutical formulation comprising a compound of formula (I), (Ia) or (Ib) or a pharmaceutically acceptable salt, solvate, or physiologically functional derivative thereof, and a pharmaceutically acceptable carrier or excipient, and optionally one or more other therapeutic ingredients.

30 Hereinafter, the term "active ingredient" means a compound of formula (I), (Ia) or (Ib), or a pharmaceutically acceptable salt, solvate, or physiologically functional derivative thereof.

- The formulations include those suitable for oral, parenteral (including subcutaneous, intradermal, intramuscular, intravenous and intraarticular), inhalation (including fine particle dusts or mists which may be generated by means of various types of metered dose pressurised aerosols, nebulisers or insufflators), rectal and topical (including dermal, buccal, sublingual and intraocular) administration although the most suitable route may depend upon for example the condition and disorder of the recipient. The formulations may conveniently be presented in unit dosage form and may be prepared by any of the methods well known in the art of pharmacy. All methods include the step of bringing the active ingredient into association with the carrier which constitutes one or more accessory ingredients. In general the formulations are prepared by uniformly and intimately bringing into association the active ingredient with liquid carriers or finely divided solid carriers or both and then, if necessary, shaping the product into the desired formulation.
- Formulations of the present invention suitable for oral administration may be presented as discrete units such as capsules, cachets or tablets each containing a predetermined amount of the active ingredient; as a powder or granules; as a solution or a suspension in an aqueous liquid or a non-aqueous liquid; or as an oil-in-water liquid emulsion or a water-in-oil liquid emulsion. The active ingredient may also be presented as a bolus, electuary or paste.
- A tablet may be made by compression or moulding, optionally with one or more accessory ingredients. Compressed tablets may be prepared by compressing in a suitable machine the active ingredient in a free-flowing form such as a powder or granules, optionally mixed with a binder, lubricant, inert diluent, lubricating, surface active or dispersing agent. Moulded tablets may be made by moulding in a suitable machine a mixture of the powdered compound moistened with an inert liquid diluent. The tablets may optionally be coated or scored and may be formulated so as to provide slow or controlled release of the active ingredient therein.
- Formulations for parenteral administration include aqueous and non-aqueous sterile injection solutions which may contain anti-oxidants, buffers, bacteriostats and solutes which render the formulation isotonic with the blood of the intended recipient; and aqueous and non-aqueous sterile suspensions which may include suspending agents and thickening agents. The formulations may be presented in unit-dose or multi-dose

containers, for example sealed ampoules and vials, and may be stored in a freeze-dried (lyophilised) condition requiring only the addition of the sterile liquid carrier, for example saline or water-for-injection, immediately prior to use. Extemporaneous injection solutions and suspensions may be prepared from sterile powders, granules and tablets 5 of the kind previously described.

Dry powder compositions for topical delivery to the lung by inhalation may, for example, be presented in capsules and cartridges of for example gelatine, or blisters of for 10 example laminated aluminium foil, for use in an inhaler or insufflator. Formulations generally contain a powder mix for inhalation of the compound of the invention and a suitable powder base (carrier substance) such as lactose or starch. Use of lactose is preferred. Each capsule or cartridge may generally contain between 20 μ g-10mg of the compound of formula (I) optionally in combination with another therapeutically active ingredient. Alternatively, the compound of the invention may be presented without 15 excipients. Packaging of the formulation may be suitable for unit dose or multi-dose delivery. In the case of multi-dose delivery, the formulation can be pre-metered (eg as in Diskus, see GB 2242134 or Diskhaler, see GB 2178965, 2129691 and 2169265) or metered in use (eg as in Turbuhaler, see EP 69715). An example of a unit-dose device is Rotahaler (see GB 2064336). The Diskus inhalation device comprises an elongate 20 strip formed from a base sheet having a plurality of recesses spaced along its length and a lid sheet hermetically but peelably sealed thereto to define a plurality of containers, each container having therein an inhalable formulation containing a compound of formula (I) preferably combined with lactose. Preferably, the strip is sufficiently flexible to be wound into a roll. The lid sheet and base sheet will preferably 25 have leading end portions which are not sealed to one another and at least one of the said leading end portions is constructed to be attached to a winding means. Also, preferably the hermetic seal between the base and lid sheets extends over their whole width. The lid sheet may preferably be peeled from the base sheet in a longitudinal direction from a first end of the said base sheet.

30

Spray compositions for topical delivery to the lung by inhalation may for example be formulated as aqueous solutions or suspensions or as aerosols delivered from pressurised packs, such as a metered dose inhaler, with the use of a suitable liquefied propellant. Aerosol compositions suitable for inhalation can be either a suspension or a

solution and generally contain the compound of formula (I) optionally in combination with another therapeutically active ingredient and a suitable propellant such as a fluorocarbon or hydrogen-containing chlorofluorocarbon or mixtures thereof, particularly hydrofluoroalkanes, e.g. dichlorodifluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane, especially 1,1,1,2-tetrafluoroethane, 1,1,1,2,3,3-heptafluoro-n-propane or a mixture thereof. Carbon dioxide or other suitable gas may also be used as propellant. The aerosol composition may be excipient free or may optionally contain additional formulation excipients well known in the art such as surfactants eg oleic acid or lecithin and cosolvents eg ethanol. Pressurised formulations will generally be retained in a canister (eg an aluminium canister) closed with a valve (eg a metering valve) and fitted into an actuator provided with a mouthpiece.

Medicaments for administration by inhalation desirably have a controlled particle size. The optimum particle size for inhalation into the bronchial system is usually 1-10 μm , preferably 2-5 μm . Particles having a size above 20 μm are generally too large when inhaled to reach the small airways. To achieve these particle sizes the particles of the active ingredient as produced may be size reduced by conventional means eg by micronisation. The desired fraction may be separated out by air classification or sieving. Preferably, the particles will be crystalline. When an excipient such as lactose is employed, generally, the particle size of the excipient will be much greater than the inhaled medicament within the present invention. When the excipient is lactose it will typically be present as milled lactose, wherein not more than 85% of lactose particles will have a MMD of 60-90 μm and not less than 15% will have a MMD of less than 15 μm .

Intranasal sprays may be formulated with aqueous or non-aqueous vehicles with the addition of agents such as thickening agents, buffer salts or acid or alkali to adjust the pH, isotonicity adjusting agents or anti-oxidants.

Capsules and cartridges or for example gelatin, or blisters of for example laminated aluminium foil, for use in an inhaler or insulator may be formulated containing a powder mix of a compound of the invention and a suitable powder base such as lactose or starch.

Solutions for inhalation by nebulisation may be formulated with an aqueous vehicle with the addition of agents such as acid or alkali, buffer salts, isotonicity adjusting agents or antimicrobials. They may be sterilised by filtration or heating in an autoclave, or
5 presented as a non-sterile product.

- Formulations for rectal administration may be presented as a suppository with the usual carriers such as cocoa butter or polyethylene glycol.
- 10 Formulations for topical administration in the mouth, for example buccally or sublingually, include lozenges comprising the active ingredient in a flavoured basis such as sucrose and acacia or tragacanth, and pastilles comprising the active ingredient in a basis such as gelatin and glycerin or sucrose and acacia.
- 15 Preferred unit dosage formulations are those containing an effective dose, as hereinbefore recited, or an appropriate fraction thereof, of the active ingredient.

It should be understood that in addition to the ingredients particularly mentioned above, the formulations of this invention may include other agents conventional in the art
20 having regard to the type of formulation in question, for example those suitable for oral administration may include flavouring agents.
The compounds and pharmaceutical formulations according to the invention may be used in combination with or include one or more other therapeutic agents, for example anti-inflammatory agents, anticholinergic agents (particularly an M₁, M₂, M₁/M₂ or M₃
25 receptor antagonist), other β₂-adrenoreceptor agonists, antiinfective agents (e.g. antibiotics, antivirals), or antihistamines. The invention thus provides, in a further aspect, a combination comprising a compound of formula (I) or a pharmaceutically acceptable salt, solvate or physiologically functional derivative thereof together with one or more other therapeutically active agents, for example, an anti-inflammatory agent (for
30 example a corticosteroid or an NSAID), an anticholinergic agent, another β₂-adrenoreceptor agonist, an antiinfective agent (e.g. an antibiotic or an antiviral), or an antihistamine. Preferred are combinations comprising a compound of formula (I) or a pharmaceutically acceptable salt, solvate or physiologically functional derivative thereof together with a corticosteroid, and/or an anticholinergic, and/or a PDE-4 inhibitor.
35 Preferred combinations are those comprising one or two other therapeutic agents.

It will be clear to a person skilled in the art that, where appropriate, the other therapeutic ingredient(s) may be used in the form of salts, (e.g. as alkali metal or amine salts or as acid addition salts), or prodrugs, or as esters (e.g. lower alkyl esters), or as solvates (e.g. hydrates) to optimise the activity and/or stability and/or physical characteristics (e.g. solubility) of the therapeutic ingredient. It will be clear also that where appropriate, the therapeutic ingredients may be used in optically pure form.

Suitable anti-inflammatory agents include corticosteroids and NSAIDs. Suitable corticosteroids which may be used in combination with the compounds of the invention are those oral and inhaled corticosteroids and their pro-drugs which have anti-inflammatory activity. Examples include methyl prednisolone, prednisolone, dexamethasone, fluticasone propionate, 6 α ,9 α -difluoro-17 α -[(2-furanylcarbonyl)oxy]-11 β -hydroxy-16 α -methyl-3-oxo-androsta-1,4-diene-17 β -carbothioic acid S-fluoromethyl ester, 6 α ,9 α -difluoro-11 β -hydroxy-16 α -methyl-3-oxo-17 α -propionyloxy- androsta-1,4-diene-17 β -carbothioic acid S-(2-oxo-tetrahydro-furan-3S-yl) ester, beclomethasone esters (e.g. the 17-propionate ester or the 17,21-dipropionate ester), budesonide, flunisolide, mometasone esters (e.g. the furoate ester), triamcinolone acetonide, rofleponide, ciclesonide, butixocort propionate, RPR-106541, and ST-126. Preferred corticosteroids include fluticasone propionate, and 6 α ,9 α -difluoro-17 α -[(2-furanylcarbonyl)oxy]-11 β -hydroxy-16 α -methyl-3-oxo-androsta-1,4-diene-17 β -carbothioic acid S-fluoromethyl ester, more preferably 6 α ,9 α -difluoro-17 α -[(2-furanylcarbonyl)oxy]-11 β -hydroxy-16 α -methyl-3-oxo-androsta-1,4-diene-17 β -carbothioic acid S-fluoromethyl ester.

Suitable NSAIDs include sodium cromoglycate, nedocromil sodium, phosphodiesterase (PDE) inhibitors (e.g. theophylline, PDE4 inhibitors or mixed PDE3/PDE4 inhibitors), leukotriene antagonists, inhibitors of leukotriene synthesis, iNOS inhibitors, tryptase and elastase inhibitors, beta-2 integrin antagonists and adenosine receptor agonists or antagonists (e.g. adenosine 2a agonists), cytokine antagonists (e.g. chemokine antagonists) or inhibitors of cytokine synthesis. Suitable other β_2 -adrenoreceptor agonists include salmeterol (e.g. as the xinafoate), salbutamol (e.g. as the sulphate or

the free base), formoterol (e.g. as the fumarate), fenoterol or terbutaline and salts thereof.

Of particular interest is use of the compound of formula (I) in combination with a phosphodiesterase 4 (PDE4) inhibitor or a mixed PDE3/PDE4 inhibitor. The PDE4-specific inhibitor useful in this aspect of the invention may be any compound that is known to inhibit the PDE4 enzyme or which is discovered to act as a PDE4 inhibitor, and which are only PDE4 inhibitors, not compounds which inhibit other members of the PDE family as well as PDE4. Generally it is preferred to use a PDE4 inhibitor which has an IC₅₀ ratio of about 0.1 or greater as regards the IC₅₀ for the PDE4 catalytic form which binds rolipram with a high affinity divided by the IC₅₀ for the form which binds rolipram with a low affinity. For the purposes of this disclosure, the cAMP catalytic site which binds R and S rolipram with a low affinity is denominated the "low affinity" binding site (LPDE 4) and the other form of this catalytic site which binds rolipram with a high affinity is denominated the "high affinity" binding site (HPDE 4). This term "HPDE4" should not be confused with the term "hPDE4" which is used to denote human PDE4.

A method for determining IC₅₀s ratios is set out in US patent 5,998,428 which is incorporated herein in full by reference as though set out herein. See also PCT application WO 00/51599 for an another description of said assay.

The preferred PDE4 inhibitors of use in this invention will be those compounds which have a salutary therapeutic ratio, i.e., compounds which preferentially inhibit cAMP catalytic activity where the enzyme is in the form that binds rolipram with a low affinity, thereby reducing the side effects which apparently are linked to inhibiting the form which binds rolipram with a high affinity. Another way to state this is that the preferred compounds will have an IC₅₀ ratio of about 0.1 or greater as regards the IC₅₀ for the PDE4 catalytic form which binds rolipram with a high affinity divided by the IC₅₀ for the form which binds rolipram with a low affinity.

A further refinement of this standard is that of one wherein the PDE4 inhibitor has an IC₅₀ ratio of about 0.1 or greater; said ratio is the ratio of the IC₅₀ value for competing with the binding of 1nM of [³H]R-rolipram to a form of PDE4 which binds rolipram with a

high affinity over the IC₅₀ value for inhibiting the PDE4 catalytic activity of a form which binds rolipram with a low affinity using 1 µM [³H]-cAMP as the substrate.

Examples of useful PDE4 inhibitors are:

- 5 (R)-(+)-1-(4-bromobenzyl)-4-[(3-cyclopentyloxy)-4-methoxyphenyl]-2-pyrrolidone;
 (R)-(+)-1-(4-bromobenzyl)-4-[(3-cyclopentyloxy)-4-methoxyphenyl]-2-pyrrolidone;
 3-(cyclopentyloxy-4-methoxyphenyl)-1-(4-N'-[N2-cyano-S-methyl-isothioureido]benzyl)-
 2-pyrrolidone;
 cis 4-cyano-4-(3-cyclopentyloxy-4-methoxyphenyl)cyclohexan-1-carboxylic acid];
10 cis-[4-cyano-4-(3-cyclopropylmethoxy-4-difluoromethoxyphenyl)cyclohexan-1-ol];
 (R)-(+)-ethyl [4-(3-cyclopentyloxy-4-methoxyphenyl)pyrrolidine-2-ylidene]acetate; and
 (S)-(-)-ethyl [4-(3-cyclopentyloxy-4-methoxyphenyl)pyrrolidine-2-ylidene]acetate.

Most preferred are those PDE4 inhibitors which have an IC₅₀ ratio of greater than 0.5,
15 and particularly those compounds having a ratio of greater than 1.0. Preferred
compounds are *cis* 4-cyano-4-(3-cyclopentyloxy-4-methoxyphenyl)cyclohexan-1-
carboxylic acid, 2-carbomethoxy-4-cyano-4-(3-cyclopropylmethoxy-4-
difluoromethoxyphenyl)cyclohexan-1-one and *cis*-[4-cyano-4-(3-cyclopropylmethoxy-4-
difluoromethoxyphenyl)cyclohexan-1-ol]; these are examples of compounds which bind
20 preferentially to the low affinity binding site and which have an IC₅₀ ratio of 0.1 or
greater.

Other compounds of interest include:

Compounds set out in U.S. patent 5,552,438 issued 03 September, 1996; this patent
25 and the compounds it discloses are incorporated herein in full by reference. The
compound of particular interest, which is disclosed in U.S. patent 5,552,438, is *cis*-4-
cyano-4-[3-(cyclopentyloxy)-4-methoxyphenyl]cyclohexane-1-carboxylic acid (also
known as cilomastat) and its salts, esters, pro-drugs or physical forms;
 AWD-12-281 from Asta Medica (Hofgen, N. et al. 15th EFMC Int Symp Med Chem
30 (Sept 6-10, Edinburgh) 1998, Abst P.98; CAS reference No. 247584020-9); a 9-
benzyladenine derivative nominated NCS-613 (INSERM); D-4418 from Chiroscience
and Schering-Plough; a benzodiazepine PDE4 inhibitor identified as CI-1018 (PD-
168787) and attributed to Pfizer; a benzodioxole derivative disclosed by Kyowa Hakko


in WO99/16766; K-34 from Kyowa Hakko; V-11294A from Napp (Landells, L.J. *et al.* Eur Resp J [Annu Cong Eur Resp Soc (Sept 19-23, Geneva) 1998] 1998, 12 (Suppl. 28): Abst P2393); roflumilast (CAS reference No 162401-32-3) and a pthalazinone (WO99/47505, the disclosure of which is hereby incorporated by reference) from Byk-Gulden; Pumafentrine, (-)-p-[(4aR*,10bS*)-9-ethoxy-1,2,3,4,4a,10b-hexahydro-8-methoxy-2-methylbenzo[c][1,6]naphthyridin-6-yl]-N,N-diisopropylbenzamide which is a mixed PDE3/PDE4 inhibitor which has been prepared and published on by Byk-Gulden, now Altana; arofylline under development by Almirall-Prodesfarma; VM554/UM565 from Vemalis; or T-440 (Tanabe Seiyaku; Fuji, K. *et al.* J Pharmacol Exp Ther, 1998, 284(1): 162), and T2585.

Other possible PDE-4 and mixed PDE3/PDE4 inhibitors include those listed in WO01/13953, the disclosure of which is hereby incorporated by reference.

- 15 Suitable anticholinergic agents are those compounds that act as antagonists at the muscarinic receptor, in particular those compounds which are antagonists of the M₁ and M₂ receptors. Exemplary compounds include the alkaloids of the belladonna plants as illustrated by the likes of atropine, scopolamine, homatropine, hyoscyamine; these compounds are normally administered as a salt, being tertiary amines. These drugs, particularly the salt forms, are readily available from a number of commercial sources or can be made or prepared from literature data via, to wit:
- 20 Atropine - CAS-51-55-8 or CAS-51-48-1 (anhydrous form), atropine sulfate - CAS-5908-99-6; atropine oxide - CAS-4438-22-6 or its HCl salt - CAS-4574-60-1 and methylatropine nitrate - CAS-52-88-0.
- 25 Homatropine - CAS-87-00-3, hydrobromide salt - CAS-51-56-9, methylbromide salt - CAS-80-49-9.
- Hyoscyamine (*d, l*) - CAS-101-31-5, hydrobromide salt - CAS-306-03-6 and sulfate salt - CAS-6835-16-1.
- 30 Scopolamine - CAS-51-34-3, hydrobromide salt - CAS-6533-68-2, methylbromide salt - CAS-155-41-9.
- Preferred anticholinergics include ipratropium (e.g. as the bromide), sold under the name Atrovent, oxitropium (e.g. as the bromide) and tiotropium (e.g. as the bromide) (CAS-139404-48-1). Also of interest are: methantheline (CAS-53-46-3), propantheline

bromide (CAS- 50-34-9), anisotropine methyl bromide or Valpin 50 (CAS- 80-50-2), clidinium bromide (Quarzan, CAS-3485-62-9), copyrrolate (Robinul), isopropamide iodide (CAS-71-81-8), mepenzolate bromide (U.S. patent 2,918,408), tridihexethyl chloride (Pathilone, CAS-4310-35-4), and hexocyclium methylsulfate (Tral, CAS-115-63-9). See also cyclopentolate hydrochloride (CAS-5870-29-1), tropicamide (CAS-1508-75-4), trihexyphenidyl hydrochloride (CAS-144-11-6), pirenzepine (CAS-29868-97-1), telenzepine (CAS-80880-90-9), AF-DX 116, or methocramine, and the compounds disclosed in WO01/04118, the disclosure of which is hereby incorporated by reference.

Suitable antihistamines (also referred to as H₁-receptor antagonists) include any one or more of the numerous antagonists known which inhibit H₁-receptors, and are safe for human use. All are reversible, competitive inhibitors of the interaction of histamine with H₁-receptors. The majority of these inhibitors, mostly first generation antagonists, have a core structure, which can be represented by the following formula:



This generalized structure represents three types of antihistamines generally available:
ethanolamines, ethylenediamines, and alkylamines. In addition, other first generation
antihistamines include those which can be characterized as based on piperazine and
phenothiazines. Second generation antagonists, which are non-sedating, have a
similar structure-activity relationship in that they retain the core ethylene group (the
alkylamines) or mimic the tertiary amine group with piperazine or piperidine. Exemplary
antagonists are as follows:

Ethanolamines: carboxinamine maleate, clemastine fumarate, diphenylhydramine hydrochloride, and dimenhydrinate.
Ethylenediamines: pyrilamine amleate, tripelennamine HCl, and tripelennamine citrate.
Alkylamines: chlorpheniramine and its salts such as the maleate salt, and acrivastine.
Piperazines: hydroxyzine HCl, hydroxyzine pamoate, cyclizine HCl, cyclizine lactate,
meclizine HCl, and cetirizine HCl.

Piperidines: Astemizole, levocabastine HCl, loratadine or its descarboethoxy analogue, and terfenadine and fexofenadine hydrochloride or another pharmaceutically acceptable salt.

5 Azelastine hydrochloride is yet another H₁ receptor antagonist which may be used in combination with a PDE4 inhibitor.

Examples of preferred anti-histamines include methapyrilene and loratadine.

10 The invention thus provides, in a further aspect, a combination comprising a compound of formula (I) a pharmaceutically acceptable salt, solvate or physiologically functional derivative thereof together with a PDE4 inhibitor.

The invention thus provides, in a further aspect, a combination comprising a compound of formula (I) a pharmaceutically acceptable salt, solvate or physiologically functional derivative thereof together with a corticosteroid.

15 The invention thus provides, in a further aspect, a combination comprising a compound of formula (I) a pharmaceutically acceptable salt, solvate or physiologically functional derivative thereof together with an anticholinergic.

20 The invention thus provides, in a further aspect, a combination comprising a compound of formula (I) a pharmaceutically acceptable salt, solvate or physiologically functional derivative thereof together with an antihistamine.

25 The invention thus provides, in a further aspect, a combination comprising a compound of formula (I) a pharmaceutically acceptable salt, solvate or physiologically functional derivative thereof together with a PDE4 inhibitor and a corticosteroid.

30 The invention thus provides, in a further aspect, a combination comprising a compound of formula (I) a pharmaceutically acceptable salt, solvate or physiologically functional derivative thereof together with an anticholinergic and a PDE-4 inhibitor.

The combinations referred to above may conveniently be presented for use in the form of a pharmaceutical formulation and thus pharmaceutical formulations comprising a


combination as defined above together with a physiologically acceptable diluent or carrier represent a further aspect of the invention.

The individual compounds of such combinations may be administered either sequentially or simultaneously in separate or combined pharmaceutical formulations. Appropriate doses of known therapeutic agents will be readily appreciated by those skilled in the art.

According to a further aspect of the invention, there is provided a process for preparing a compound of formula (I), (Ia) or (Ib) or a salt, solvate, or physiologically functional derivative thereof which comprises a process (a) or (b) as defined below followed by the following steps in any order:


- (i) optional removal of any protecting groups;
- (ii) optional separation of an enantiomer from a mixture of enantiomers;
- 15 (iii) optional conversion of the product to a corresponding salt, solvate, or physiologically functional derivative thereof.

In one general process (a), a compound of formula (I), (Ia) or (Ib) may be obtained by deprotection of a protected intermediate, for example of formula (II):


20 

or a salt or solvate thereof, wherein R¹, R², R³, R⁴, R⁵, m, and n are as defined for the compound of formula (I), (Ia) or (Ib), Ar^{1a} represents an optionally protected form of Ar¹; and P¹ and P² are each independently either hydrogen or a protecting group, provided that the compound of formula (II) contains at least one protecting group.


Protected forms of the preferred groups Ar¹ may be selected from:




(ia)




(iia)



(iiiia)



(iva)




(va)

(via)

(viiia)

(viiiia)




(ixa)

(xa)

(xiia)

(xiia)


5



(xiiia)

(xiva)

(xva)




(xvia)




(xviiia)




(xviiiia)



(xixa)



(xxa)




(xxia)

wherein P³ and P⁴ are each independently either hydrogen or a protecting group
 5 provided that at least one of P³ and P⁴ is a protecting group, and the dotted line in (xvia)
 and (xixa) denotes an optional double bond.

Suitable protecting groups may be any conventional protecting group such as those described in "Protective Groups in Organic Synthesis" by Theodora W Greene and Peter G M Wuts, 3rd edition (John Wiley & Sons, 1999). Examples of suitable hydroxyl protecting groups represented by P³ and P⁴ are esters such as acetate ester, aralkyl groups such as benzyl, diphenylmethyl, or triphenylmethyl, and tetrahydropyranyl. Examples of suitable amino protecting groups represented by P² include benzyl, α-methylbenzyl, diphenylmethyl, triphenylmethyl, benzyloxycarbonyl, tert-butoxycarbonyl, and acyl groups such as trichloroacetyl or trifluoroacetyl.
 10
 15

As will be appreciated by the person skilled in the art, use of such protecting groups may include orthogonal protection of groups in the compounds of formula (II) to facilitate the selective removal of one group in the presence of another, thus enabling selective functionalisation of a single amino or hydroxyl function. For example, the $-\text{CH}(\text{OH})$ group may be orthogonally protected as $-\text{CH}(\text{OP}^1)$ using, for example, a trialkylsilyl group such as triethylsilyl. A person skilled in the art will also appreciate other orthogonal protection strategies, available by conventional means as described in Theodora W Greene and Peter G M Wuts (see above).


- 5 group may be orthogonally protected as $-\text{CH}(\text{OP}^1)$ using, for example, a trialkylsilyl
group such as triethylsilyl. A person skilled in the art will also appreciate other
orthogonal protection strategies, available by conventional means as described in
Theodora W Greene and Peter G M Wuts (see above).
- 10 The deprotection to yield a compound of formula (I), (I) or (Ib) may be effected using conventional techniques. Thus, for example, when P^2 , P^3 , and/or P^4 is an aralkyl group, this may be cleaved by hydrogenolysis in the presence of a metal catalyst (e.g. palladium on charcoal).
- 15 When P^3 and/or P^4 is tetrahydropyranyl this may be cleaved by hydrolysis under acidic conditions. Acyl groups represented by P^2 may be removed by hydrolysis, for example with a base such as sodium hydroxide, or a group such as trichloroethoxycarbonyl may be removed by reduction with, for example, zinc and acetic acid. Other deprotection methods may be found in Theodora W Greene and Peter G M Wuts (see above). In a
20 particular embodiment of process (a), P^3 and P^4 may together represent a protecting group as in the compound of formula (III):



- 25 or a salt or solvate thereof, wherein R^1 , R^2 , R^3 , R^4 , R^5 , R^{14} , P^1 , P^2 , m , and n are as defined for the compound of formula (I), (Ia) or (Ib), and R^{24} and R^{25} are independently selected from hydrogen, C_{1-6} alkyl, or aryl or R^{24} and R^{25} together form a C_{3-7} cycloalkyl ring. In a preferred aspect, both R^{24} and R^{25} are methyl.

5 The compound of formula (III) may be converted to a compound of formula (I), (Ia) or (Ib) by hydrolysis with dilute aqueous acid, for example acetic acid or hydrochloric acid in a suitable solvent or by transketolisation in an alcohol, for example ethanol, in the presence of a catalyst such as an acid (for example, toluenesulphonic acid or a sulphonic acid ion exchange column such as SCX-2) or a salt (such as pyridinium tosylate) at normal or elevated temperature.


10 Compounds of formulae (II) and (III) wherein P² is hydrogen may be prepared from the corresponding compound of formula (IV):




20 or a salt or solvate thereof, wherein R¹, R², R³, R⁴, R⁵, Ar^{1a}, m, and n are as defined for the compound of formula (II) or (III).

25 The conversion of a compound of formula (IV) to a compound of formula (II) or (III) may be effected by treatment with a base, for example a non-aqueous base, such as potassium trimethylsilanolate, or an aqueous base such as aqueous sodium hydroxide, in a suitable solvent such as tetrahydrofuran.

Compounds of formula (IV) may be prepared from the corresponding compound of formula (V):



or a salt or solvate thereof, wherein R⁴, R⁵, Ar^{1a}, m and n are as defined for the compound of formula (IV);
by coupling with a compound of formula (VI) or a precursor thereof:



wherein R^1 , R^2 , and R^3 are as defined for the compound of formula (IV) and L is a leaving group, such as a halo group (typically, bromo or iodo) or a sulphonate ester such as a haloalkyl sulphonate (typically, trifluoromethanesulphonate).


A suitable precursor of the compound of formula (VI) would be a compound of formula (VI) in which one or more of the substituents R^1 , R^2 , and R^3 is a group which is convertible to the desired group R^1 , R^2 , and/or R^3 . For example, where R^1 is to be $-(CH_2)_pNR^6C(O)NR^7R^8$, a suitable precursor of the compound of formula (VI) would have the primary amine $-(CH_2)_pNH_2$ in place of the substituent R^1 , such that the desired substituent R^1 may be formed by reaction with the appropriate isocyanate (i.e. R^7NCO) after the coupling with the compound of formula (V). Alternatively, R^1 is $-XNCO$ (wherein X is as hereinbefore defined) which is coupled with an amine R^7NH_2 using standard procedures.

The coupling of compound of formula (V) with a compound of formula (VI) or a precursor thereof is conveniently effected in the presence of a catalyst system such as bis (triphenylphosphine) palladium dichloride with an organic base such as a trialkylamine, for example, triethylamine, in a suitable solvent, for example acetonitrile or dimethylformamide. The resulting alkyne may then be reduced, either with or without being isolated to form the compound of formula (IV). The reduction may be effected by any suitable method such as hydrogenation in the presence of a catalyst, for example, palladium/charcoal or platinum oxide.


Alternatively, after coupling of a compound of formula (V) to a compound of formula (VI), the resulting compound may be treated with a base, for example a non-aqueous base such as potassium trimethylsilanolate, or an aqueous base such as aqueous sodium hydroxide, in a suitable solvent such as tetrahydrofuran, followed by reduction of the alkyne group to form a compound of formula (II) wherein R^{10} denotes hydrogen.

Compounds of formula (VI) are commercially available or may be prepared by methods well known to the person skilled in the art.

- 5 Compounds of formula (V) may be prepared by coupling a compound of formula (VII):



- 10 or a salt or solvate thereof, wherein Ar^{1a} is defined for the compound of formula (V) with a compound of formula (VIII):




- 15 wherein R⁴, R⁵, m and n are as defined for the compound of formula (V) and L¹ is a leaving group, for example a halo group (typically bromo or iodo) or a sulphonate such as an alkyl sulphonate (typically, methanesulphonate), an arylsulphonate (typically, toluenesulphonate), or a haloalkyl sulphonate (typically, trifluoromethanesulphonate).

- 20 The coupling of a compound of formula (VII) with a compound of formula (VIII) may be effected in the presence of a base, such as a metal hydride, for example sodium hydride, or an inorganic base such as caesium carbonate, in an aprotic solvent, for example dimethylformamide.

- 25 Compounds of formula (VIII) may be prepared from the corresponding dihaloalkane and hydroxyalkyne by conventional chemistry, typically in the presence of an inorganic base, such as aqueous sodium hydroxide, under phase transfer conditions in the presence of a salt such as tetraalkylammonium bromide.

- 30 Compounds of formula (VII) may be prepared by ring closure of a compound of formula (IX):




wherein Ar^{1a} is defined for the compound of formula (VII) and R²⁶ is C₁₋₆alkyl, for example tert-butyl, or aryl, for example phenyl. The ring closure may be effected by treatment with a base, such as a metal hydride, for example sodium hydride, in the presence of an aprotic solvent, for example, dimethylformamide. Preparation of compounds (VII) wherein Ar^{1a} is a group (ia) is described in W002/066422.

5

Compounds of formula (IX) may be prepared from the corresponding ketone of formula (X):

10



wherein Ar^{1a} and R²⁶ are as defined for the compound of formula (IX), by reduction by any suitable method, for example by treatment with borane, in the presence of a chiral catalyst, such as CBS-oxazaborolidine, in a suitable solvent such as tetrahydrofuran.

15

The compound of formula (X) may be prepared from the corresponding halide of formula (XI)



20

wherein Ar^{1a} as defined for the compound of formula (X) and Y is halo, suitably bromo.

25


The conversion of a compound of formula (XI) to a compound of formula (X) may be effected by reaction with the protected amine HN(COOR²⁶)₂ wherein R²⁶ is as defined for the compound of formula (X) in the presence of an inorganic base such as caesium carbonate, followed by selective removal of one of the COOR¹³ groups, for example by treatment with an acid such as trifluoroacetic acid.

30

Compounds of formula (XI) may be prepared for example as described in DE 3513885 (Glaxo).

In a further process (b), a compound of formula (I), (Ia) or (Ib) may be obtained by alkylation of an amine of formula (XII)


5



wherein Ar^{1a} and P² are as hereinbefore defined;

with a compound of formula (XIII):

10



wherein R¹, R², R³, R⁴, R⁵, m, and n are as defined for the compound of formula (I), (Ia) or (Ib) and L¹ is a leaving group such as halo (typically bromo); followed by removal of

15 any protecting groups present by conventional methods as described above for the deprotection of compounds of formula (II).

The reaction of compounds of formulae (XII) and (XIII) is optionally effected in the presence of an organic base such as a trialkylamine, for example,

20 diisopropylethylamine, and in a suitable solvent for example dimethyl formamide.

Compounds of formula (XII) are known in the art (for example EP-A 0947498) or may be readily prepared by a person skilled in the art.

25 Compounds of formula (XIII) may be prepared by coupling a compound of formula (VI) as defined above, or a precursor thereof (wherein one or more of the substituents R¹, R² or R³ is a group which is convertible to the desired group R¹, R², or R³) with a compound of formula (VIII) as shown above wherein R⁴, R⁵, m, and n are as defined for the compound of formula (XIII) and L¹ is a leaving group as defined above.


Suitable precursors of the compounds of formula (VI) for this purpose may be designed using the same principles as described above in relation to the coupling of a compound of formula (VI) with a compound of formula (V).

5

The coupling of a compound of formula (VIII) with a compound (VI) may be effected by methods analogous to those described above for coupling a compound of formula (V) with a compound of formula (VI), followed by reduction of the resulting alkyne, also as described above. If necessary, the substituents R¹, R², and/or R³ may be formed by conventional conversions where a precursor is present.

10

In a yet further process (c) a compound of formula (I), (Ia) or (Ib) may be obtained by reduction of a compound of formula (XIV):



15 Wherein R¹, R², R³, R⁴, R⁵, m and n are as defined for formula (I) and Ar^{1a}, P¹, and P² are defined for formula (II).


The reduction may be effected by any suitable method such as hydrogenation in the presence of a catalyst, for example, palladium/charcoal or platinum oxide.

20

It will be appreciated that where Ar^{1a} represents Ar¹, and P¹ and P² each represent hydrogen, the reduction will yield a compound of formula (I), but where one or more of Ar^{1a}, P² and P² represents or contains a protecting group then reduction will yield a compound of formula (II) or (III), which may then be deprotected to give a compound of formula (I).


25

A compound of formula (XIV) may be prepared by reacting a compound of formula (XII) as herein before defined with a compound of formula (XV):




wherein R^1 , R^2 , R^3 , R^4 , R^5 , m , and n are as defined for the compound of formula (I), (Ia) or (Ib) and L^2 is as defined for L and L^1 above.

- 5 The reaction of compounds of formulae (XIV) and (XV) is optionally effected in the presence of an organic base such as a trialkylamine, for example, diisopropylethylamine, and in a suitable solvent for example N,N-dimethylformamide.
- 10 The compound of formula (XV) may be prepared by coupling a compound of formula (VI) as defined above with a compound of formula (VIII) as defined above, as described for the first stage of the preparation of compounds (XIII), without the reduction step.
- 15 An alkyne of formula (XV) may also be prepared by reacting a compound of formula (XVI):




- 20 Wherein R^4 , R^5 and n are as defined hereinabove and L^2 and L^3 each represent a leaving group, which groups may independently be selected for example from those defined above for L and L^1 , with a compound of formula (XVII):



using conventional methods, for example as described for the preparation of compounds (VIII).


Compounds of formula (XVII) may be prepared by reacting a hydroxyalkyne




5

with a compound of formula (VI) using methods analogous to those described above for coupling a compound (V) with a compound (VI).

In a further process (d) a compound of formula (I), (Ia) or (Ib) may be prepared by reacting a compound of formula (XVIII):



wherein Ar^{1a} and P¹ are as hereinbefore defined and L⁴ is a leaving group as defined above for groups L-L³ with an amine of formula (XIX):



followed by removal of any protecting groups present by conventional methods as described above for the deprotection of compounds of formula (II).


The reaction may be effected using conventional conditions for such displacement reactions.

Compounds of formula (XVIII) may be prepared by methods known in the art.

Compounds of formula (XIX) may be prepared by reacting a compound of formula (XIII) with an amine P^2NH_2 .

5

In a further process (e) a compound of formula (I), (IIa) or (IIb) may be prepared by removal of a chiral auxiliary from a compound of formula (IIa):




10 wherein $R^1 - R^5$, m and n are as defined for formula (I), Ar^{1a} and P^1 are as defined for formula (II) and R^{27} represents a chiral auxiliary.

A "chiral auxiliary" is a moiety that is introduced into a molecule to influence the stereochemistry of the product formed, and is removed in whole or part at a later time.

15 A chiral auxiliary may simultaneously function as a protecting group.

Many chiral auxiliaries are commercially available, and persons skilled in the art would choose one based on the properties desired i.e. the absolute stereochemistry desired and compatibility with the processes being used. Chiral auxiliaries suitable for use in 20 this process include but are not limited to the S-isomer and/or the R-isomer of phenyl glycinol and substituted derivatives thereof.


The chiral auxiliary is preferably a moiety of the formula:



or a single enantiomer thereof, wherein R²⁸ represents C₁₋₆alkyl or optionally substituted phenyl or benzyl wherein the optional substitution is one or more independently selected from C₁₋₆alkyl, halogen, hydroxy, C₁₋₆alkoxy or nitro e.g. para-hydroxyphenyl.


5

More preferably the chiral auxiliary is a moiety:



wherein R²⁸ is as defined above. Alternatively it may be a moiety of formula:

10




wherein R²⁸ is as defined above.

Preferably R²⁸ represents phenyl optionally substituted as described above. Most 15 preferably R²⁸ represents unsubstituted phenyl.

The chiral auxiliary in this process may typically be removed by hydrogenolysis using for example a palladium on carbon catalyst or preferably using palladium hydroxide (Pearlman's catalyst). Advantageously when Pearlman's catalyst is used the removal of 20 the chiral auxiliary is most efficient. This method of removal is especially suitable where R²⁸ is phenyl or a substituted phenyl. Alternatively the nitrogen, to which the auxiliary is attached, may be derivatised under oxidising conditions to form the N-oxide before elimination by heating to give a secondary amine.


25 A compound of formula (IIa) may be prepared by reduction of the corresponding alkyne of formula (XIVa):



wherein R¹, R², R³, R⁴, R⁵, m and n are as defined for formula (I) and Ar^{1a}, P¹, and R²⁷ are as defined for formula (IIa).


- 5 Reduction of an alkyne of formula (XIVa) may be effected by methods well known in the art, for example by catalytic hydrogenation, using palladium on charcoal or more preferably palladium hydroxide (Pearlman's catalyst). The chiral auxiliary may also be removed under reductive conditions. Advantageously, therefore the reduction of the alkyne and removal of the chiral auxiliary may be effected concomitantly in a 'one-pot' reaction.
- 10

An alkyne of formula (XIVa) may be prepared by reaction of a compound of formula (XX):




- 15 wherein R⁴, R⁵, m and n are as defined for formula (I) and Ar^{1a}, P¹, and R²⁷ are as defined for formula (IIa) with a compound of formula (VI) under conditions described above for coupling of compounds (V) and (VI).

- 20 A compound of formula (XX) may be prepared by reacting a compound of formula (XIIa):



with an aldehyde of formula (XXI):



using known methods for effecting reductive amination, e.g. sodium triacetoxyborohydride in a solvent such as chloroform.

- 5 An aldehyde of formula (XXI) may be prepared from a corresponding halide of formula (VIII) using standard techniques such as treatment with sodium bicarbonate in a solvent such as DMSO at elevated temperature, preferably in the range 130-160°C.

A compound of formula (XIIa) may be prepared from a compound of formula (Xa):



- 10 wherein Ar^{1a}, and R²⁷ are as defined for formula (IIa), by treatment with a reducing agent such as a hydride source e.g. sodium borohydride. Preferably this process takes place in the presence of an inert metal salt such as calcium chloride suitably at non-extreme temperatures e.g. below ambient, such as 0°C. This allows the desired stereochemistry to be introduced efficiently with good enantiomeric excess at an early stage in the synthesis, using inexpensive and relatively harmless reagents.
- 15 Furthermore, the enantiomeric excess may be increased by recrystallisation of the product of this process.
- 20 A compound of formula (Xa) may be prepared from a compound of formula (XI) as hereinbefore defined by reaction with an appropriate chiral amine, e.g. (S)-phenylglycinol, in the presence of a non-nucleophilic base in an inert solvent at non-extreme temperatures.
- 25 A detailed description of a process analogous to Route (e) may be found in published International Application Number WO/0196278.
- It will be appreciated that in any of the routes (a) to (e) described above, the precise order of the synthetic steps by which the various groups and moieties are introduced
 30 into the molecule may be varied. It will be within the skill of the practitioner in the art to

ensure that groups or moieties introduced at one stage of the process will not be affected by subsequent transformations and reactions, and to select the order of synthetic steps accordingly.

- 5 The enantiomeric compounds of the invention may be obtained (i) by separation of the components of the corresponding racemic mixture, for example, by means of a chiral chromatography column, enzymic resolution methods, or preparing and separating suitable diastereoisomers, or (ii) by direct synthesis from the appropriate chiral intermediates by the methods described above.
- 10 Optional conversions of a compound of formula (I), (Ia) or (Ib) to a corresponding salt may conveniently be effected by reaction with the appropriate acid or base. Optional conversion of a compound of formula (I), (Ia) or (Ib) to a corresponding solvate or physiologically functional derivative may be effected by methods known to those skilled
15 in the art.

According to a further aspect, the present invention provides novel intermediates for the preparation of compounds of formula (I), (Ia) or (Ib), for example:
compounds of formula (II) and (III) as defined above, or an optical isomer, a salt, or a
20 protected derivative thereof; particularly, a compound selected from:

- N-(3-{4-[(6-[(2R)-2-(2,2-dimethyl-4H-1,3-benzodioxin-6-yl)-2-hydroxyethyl]amino}hexyl)oxy]butyl}phenyl)-N'-(4-fluorophenyl)urea ;
N-(3-{4-[(6-[(2R)-2-(2,2-dimethyl-4H-1,3-benzodioxin-6-yl)-2-hydroxyethyl]amino}hexyl)oxy]butyl}phenyl)-N'-(2,6-dichlorophenyl)urea;
25 N-(3-{4-[(6-[(2R)-2-(2,2-dimethyl-4H-1,3-benzodioxin-6-yl)-2-hydroxyethyl]amino}hexyl)oxy]butyl}phenyl)-N'-(4-methylphenyl)urea ;
{{(3-{4-[(6-[(2R)-2-(2,2-dimethyl-4H-1,3-benzodioxin-6-yl)-2-hydroxyethyl]amino}hexyl)oxy]butyl}anilino)carbonyl]amino}acetic acid ;
30 N-(3-{4-[(6-[(2R)-2-(2,2-dimethyl-4H-1,3-benzodioxin-6-yl)-2-hydroxyethyl]amino}hexyl)oxy]butyl}phenyl)-N'-[3-(trifluoromethyl)phenyl]urea;
N-(3-{4-[(6-[(2R)-2-(2,2-dimethyl-4H-1,3-benzodioxin-6-yl)-2-hydroxyethyl]amino}hexyl)oxy]butyl}phenyl)-N'-(2,6-dimethylphenyl)urea;
N-(3-{4-[(6-[(2R)-2-(2,2-dimethyl-4H-1,3-benzodioxin-6-yl)-2-hydroxyethyl]amino}hexyl)oxy]butyl}phenyl)-N'-phenylurea ;
35

- N-(3-{4-[(6-[(2R)-2-(2,2-dimethyl-4H-1,3-benzodioxin-6-yl)-2-hydroxyethyl]amino}hexyl)oxy]butyl}phenyl)-N'-ethylurea;
Ethyl {[3-{4-[(6-[(2R)-2-(2,2-dimethyl-4H-1,3-benzodioxin-6-yl)-2-hydroxyethyl]amino}hexyl)oxy]butyl}anilino)carbonyl]amino}acetate;
- 5 N-Cyclohexyl-N'-(3-{4-[(6-[(2R)-2-(2,2-dimethyl-4H-1,3-benzodioxin-6-yl)-2-hydroxyethyl]amino}hexyl)oxy]butyl}phenyl)urea;
N-(4-{4-[(6-[(2R)-2-(2,2-dimethyl-4H-1,3-benzodioxin-6-yl)-2-hydroxyethyl]amino}hexyl)oxy]butyl}phenyl)-N'-phenylurea;
N-(4-{4-[(6-[(2R)-2-(2,2-dimethyl-4H-1,3-benzodioxin-6-yl)-2-hydroxyethyl]amino}hexyl)oxy]butyl}phenyl)-N'-ethylurea;
- 10 N-(3-{4-[(6-[(2R)-2-(2,2-dimethyl-4H-1,3-benzodioxin-6-yl)-2-hydroxyethyl]amino}hexyl)oxy]butyl}phenyl)-N'-pyridin-3-ylurea;
N-[3,5-Bis(trifluoromethyl)phenyl]-N'-(3-{4-[(6-[(2R)-2-(2,2-dimethyl-4H-1,3-benzodioxin-6-yl)-2-hydroxyethyl]amino}hexyl)oxy]butyl}phenyl)urea;
- 15 N-Cyclohexyl-N'-(3-{4-[(6-[(2R)-2-(2,2-dimethyl-4H-1,3-benzodioxin-6-yl)-2-hydroxyethyl]amino}hexyl)oxy]butyl}benzyl)urea;
N-(3-{4-[(6-[(2R)-2-(2,2-dimethyl-4H-1,3-benzodioxin-6-yl)-2-hydroxyethyl]amino}hexyl)oxy]butyl}benzyl)-N'-ethylurea;
N-(3-{4-[(6-[(2R)-2-(2,2-dimethyl-4H-1,3-benzodioxin-6-yl)-2-hydroxyethyl]amino}hexyl)oxy]butyl}benzyl)urea;
- 20 N-(3-{4-[(6-[(2R)-2-(2,2-dimethyl-4H-1,3-benzodioxin-6-yl)-2-hydroxyethyl]amino}hexyl)oxy]butyl}benzyl)-N'-(4-fluorophenyl)urea;
N-(3-Chlorophenyl)-N'-(3-{4-[(6-[(2R)-2-(2,2-dimethyl-4H-1,3-benzodioxin-6-yl)-2-hydroxyethyl]amino}hexyl)oxy]butyl}benzyl)urea;
- 25 N-Benzyl-N'-(3-{4-[(6-[(2R)-2-(2,2-dimethyl-4H-1,3-benzodioxin-6-yl)-2-hydroxyethyl]amino}hexyl)oxy]butyl}benzyl)urea;
N-[(2-{4-[(6-[(2R)-2-(2,2-dimethyl-4H-1,3-benzodioxin-6-yl)-2-hydroxyethyl]amino}hexyl)oxy]butyl}benzyl)amino]carbonyl]glycine;
N-[2-(3-{4-[(6-[(2R)-2-(2,2-dimethyl-4H-1,3-benzodioxin-6-yl)-2-hydroxyethyl]amino}hexyl)oxy]butyl}phenyl)ethyl]-N'-phenylurea;
- 30 N-(3-{4-[(6-[(2R)-2-(2,2-dimethyl-4H-1,3-benzodioxin-6-yl)-2-hydroxyethyl]amino}hexyl)oxy]butyl}phenyl)urea;
N-(3-{3-[(7-[(2R)-2-(2,2-dimethyl-4H-1,3-benzodioxin-6-yl)-2-hydroxyethyl]amino}heptyl)oxy]propyl}phényl)urea;

N-(3-{5-[(2R)-2-(2,2-dimethyl-4H-1,3-benzodioxin-6-yl)-2-hydroxyethyl]amino}pentyl)oxy]pentyl}phenyl)urea;

N-(3-{5-[(2R)-2-(2,2-dimethyl-4H-1,3-benzodioxin-6-yl)-2-hydroxyethyl]amino}hexyl)oxy]pentyl}phenyl)urea;

5 N-[3-{4-[(2R)-2-(2,2-dimethyl-4H-1,3-benzodioxin-6-yl)-2-hydroxyethyl]amino}hexyl)oxy]butyl]-5-(trifluoromethyl)phenyl]urea;
N-(3-{4-[(2R)-2-(2,2-dimethyl-4H-1,3-benzodioxin-6-yl)-2-hydroxyethyl]amino}hexyl)oxy]butyl}-5-methylphenyl)urea;

10 5-[4-((6-[(5R)-5-(2,2-dimethyl-4H-1,3-benzodioxin-6-yl)-2-oxo-1,3-oxazolidin-3-yl]hexyl)oxy)butyl]-1,3-dihydro-2H-benzimidazol-2-one;

5-(4-[(6-[(2R)-2-hydroxy-2-[4-hydroxy-3-(hydroxymethyl)phenyl]ethyl]amino)hexyl]oxy)butyl)-1,3-dihydro-2H-benzimidazol-2-one;

15 N-(2-{4-[(2R)-2-(2,2-dimethyl-4H-1,3-benzodioxin-6-yl)-2-hydroxyethyl]amino}hexyl)oxy]butyl}phenyl)-N'-phenylurea;

N-{3-[4-((6-[(5R)-5-(2,2-dimethyl-4H-1,3-benzodioxin-6-yl)-2-oxo-1,3-oxazolidin-3-yl]hexyl)oxy)butyl]phenyl}-N'-(3-hydroxyphenyl)urea; and
({[(3-{4-[(2R)-2-(2,2-dimethyl-4H-1,3-benzodioxin-6-yl)-2-hydroxyethyl]amino}hexyl)oxy]butyl}phenyl)amino]carbonyl]amino)(oxo)acetic acid.

20 For a better understanding of the invention, the following Examples are given by way of illustration.

SYNTHETIC EXAMPLES

25 Throughout the examples, the following abbreviations are used:

LCMS: Liquid Chromatography Mass Spectrometry

MS mass spectrum

TSP+ve thermospray mass spectrum positive mode

30 RT : retention time

THF : tetrahydofuran

DMF : N,N-dimethylformamide

EtOAc ethyl acetate

EtOH ethanol

MeOH methanol

bp : boiling point

ca : circa

h : hour(s)

5 min : minute(s)

All temperatures are given in degrees centigrade.

Silica gel refers to Merck silica gel 60 Art number 7734.

Flash silica gel refers to Merck silica gel 60 Art number 9385.

10 Biotage refers to prepacked silica gel cartridges containing KP-Sil run on flash 12i chromatography module.

Bond Elut are prepacked cartridges used in parallel purifications, normally under vacuum. These are commercially available from Varian.

SCX-2 is a solid phase extraction column pre-packed with benzene sulfonic acid resin available from International Sorbent Technology.

15

LCMS was conducted on a Supelcosil LCABZ+PLUS column (3.3 cm x 4.6 mm ID) eluting with 0.1% HCO₂H and 0.01 M ammonium acetate in water (solvent A), and 0.05% HCO₂H 5% water in acetonitrile (solvent B), using the following elution gradient
20 0-0.7 min 0%B, 0.7-4.2 min 100%B, 4.2-5.3 min 0%B, 5.3-5.5 min 0%B at a flow rate of 3 ml/min. The mass spectra were recorded on a Fisons VG Platform spectrometer using electrospray positive and negative mode (ES+ve and ES-ve).

Example 1

25 N-(4-Fluorophenyl)-N'-[3-(4-[(6-((2R)-2-hydroxy-2-[4-hydroxy-3-(hydroxymethyl)phenyl]ethyl}amino)hexy]oxy]butyl]phenyl]urea acetate

i) Di(tert-butyl) 2-(2,2-dimethyl-4H-1,3-benzodioxin-6-yl)-2-oxoethylimidodicarbonate

Caesium carbonate (70.4g) was added to a stirred suspension of 2-bromo-1-(2,2-30 dimethyl-4H-1,3-benzodioxin-6-yl)ethanone, (Glaxo, DE 3513885, 1985) (61.8g) and di-tert-butyl iminodicarboxylate (47.15g) in acetonitrile (600ml) under nitrogen. After vigorous stirring at 21° for 24 h the mixture was diluted with water (ca 800ml) and the product was extracted with diethyl ether (1litre, then 200ml). The combined organic layers were washed with brine, dried (MgSO₄) and concentrated to ca 400ml. The white crystals were collected by filtration, washed with diethyl ether and dried to give the title

compound (24.4g) δ (CDCl_3) 7.78(1H, dd, J 8, 2Hz), 7.65 (1H, brs), 6.87 (1H, d, J 8Hz), 4.97(2H, s), 4.88 (2H, s), 1.56 (6H, s) and 1.48 (18H, s) . Further concentration of the mother liquors gave additional product (13.8g). A third crop (7.1g) was obtained by chromatographing the mother liquors on silica gel, evaporating the appropriate eluate and triturating with diethyl ether.

5

ii) tert-Butyl 2-(2,2-dimethyl-4H-1,3-benzodioxin-6-yl)-2-oxoethylcarbamate

Trifluoroacetic acid (92ml) was added to a stirred solution of di(tert-butyl) 2-(2,2-dimethyl-4H-1,3-benzodioxin-6-yl)-2-oxoethylimidodicarbonate, (352.55g) in CH_2Cl_2 (3.6 litres) at 21° and the reaction was stirred for 1.5 h. Aqueous NaOH solution (1.75 litres) was added and after 10 min the phases were separated. The organic layer was washed with water, dried (MgSO_4) and evaporated to an oil. This was stored under high vacuum overnight and then triturated with hexane:ether (3:1) to give the crude product (226.61g). This was purified by recrystallisation from diethyl ether to give the *title compound* (122.78g). Further product (61.5g) was obtained from the mother liquors by evaporation and chromatography on a Biotage using 15% ethyl acetate in hexane. LCMS RT=3.37min.

15

iii) tert-Butyl (2R)-2-(2,2-dimethyl-4H-1,3-benzodioxin-6-yl)-2-hydroxyethylcarbamate

A 2M solution of borane - dimethyl sulphide in THF (28ml) was added slowly to a 1M solution of (R)-tetrahydro-1-methyl-3,3-diphenyl-1H,3H-pyrrolo[1,2-c][1,3,2]oxazaborole in toluene (56ml) at 0° under nitrogen. A solution of tert-butyl 2-(2,2-dimethyl-4H-1,3-benzodioxin-6-yl)-2-oxoethylcarbamate, (108.2g) in THF (1.3litres) was added slowly keeping the temperature below 5° followed by 2M solution of borane - dimethyl sulphide in THF (252ml) over 50 min. After 1 h, 2M HCl (170ml) was added with cooling and the mixture was partitioned between EtOAc and water . The organic layer was washed with saturated NaHCO_3 solution and brine and dried (MgSO_4). The solution was concentrated and the product purified by chromatography on flash silica gel (800g), eluting successively with hexane:EtOAc (4:1 then 3:1) to give the *title compound* (93.3g). LCMS RT=3.31min.

25

30

iv) (5R)-5-(2,2-Dimethyl-4H-1,3-benzodioxin-6-yl)-1,3-oxazolidin-2-one

tert-Butyl (2R)-2-(2,2-dimethyl-4H-1,3-benzodioxin-6-yl)-2-hydroxyethylcarbamate, (86.37g) in DMF (600ml) was added dropwise to a stirred suspension of sodium hydride (60% oil dispersion, 11.9g) in DMF (160ml) with cooling such that the internal

35

temperature remained at 0° under nitrogen. The mixture was stirred at 21° for 2 h. The mixture was re-cooled to 0° and 2M HCl (134ml) was added. The mixture was diluted with water and the product was extracted with EtOAc twice. The solution was washed with brine twice, dried (MgSO_4) and evaporated to give the *title compound* (63.55g).

5 LCMS RT=2.66min.

v) 6-Bromohexyl but-3-ynyl ether

3-Butyn-1-ol (42.4ml) was stirred vigorously with 1,6-dibromohexane (260ml) and tetrabutylammonium bisulphate (2.4g) in 50% aqueous sodium hydroxide solution (200ml) under nitrogen for 3 days. Water (ca 700ml) was added and the organic layer was separated. The aqueous layer was extracted twice with CH_2Cl_2 ($2 \times 100\text{ml}$) and the combined organic layers were washed with water, dried (MgSO_4) and concentrated. The residue in petroleum ether (bp 40 - 60°) was loaded onto a column of silica gel (1.5kg) and the column was eluted with petroleum ether (bp 40 - 60°), then 10% diethyl ether in petroleum ether (bp 40 - 60°) to give the *title compound* (103.3g), δ (CDCl_3) 3.56(2H, t, J 7Hz), 3.47(2H, t, J 7Hz), 3.42(2H, t, J 7Hz), 2.45(2H, m), 1.99(1H, t, J 2Hz), 1.87(2H, m), 1.60(2H, m) and 1.50-1.33 (4H, m).

20 vi) (5R)-3-[6-(But-3-nyloxy)hexyl]-5-(2,2-dimethyl-4H-1,3-benzodioxin-6-yl)-1,3-oxazolidin-2-one

(5R)-5-(2,2-Dimethyl-4H-1,3-benzodioxin-6-yl)-1,3-oxazolidin-2-one (10g) in DMF (100ml) was added dropwise to a stirred suspension of sodium hydride (60% oil dispersion, 2.33g) in DMF (50ml) with stirring under nitrogen and maintaining the internal temperature at 0°. Stirring was continued at 0-5° for 1 h. The mixture was re-cooled to 0° and a solution of 6-bromohexyl but-3-ynyl ether (14.7g) in DMF (50ml) was added over 1 min. The mixture was then stirred at 20 - 30° for 2 h. 2M HCl (9ml) was added and the mixture was partitioned between water and diethyl ether. The aqueous layer was extracted with more diethyl ether and the combined organic layers were washed twice with brine. After drying (MgSO_4) the solution was concentrated and loaded onto a column of silica gel (600g) set up in diethyl ether:petroleum ether (bp 40 - 60°) (1:2). The column was eluted successively with this mixture, then (1:1) and the diethyl ether to give the *title compound* (13.88g). LCMS RT=3.45min.

35 vii) (5R)-3-[4-(3-Aminophenyl)but-3-ynyl]oxy}hexyl)-5-(2,2-dimethyl-4H-1,3-benzodioxin-6-yl)-1,3-oxazolidin-2-one

To (5R)-3-[6-(but-3-nyloxy)hexyl]-5-(2,2-dimethyl-4H-1,3-benzodioxin-6-yl)-1,3-oxazolidin-2-one (1.0g) was added 3-iodoaniline (0.3ml), acetonitrile (6.0ml) and triethylamine (3ml). The resultant mixture was purged with a vigorous stream of nitrogen for 5min. Cuprous iodide (50mg) and dichlorobis(triphenylphosphine) palladium (50mg) were added and the reaction mixture was stirred at room temperature under nitrogen for 3h. The mixture was evaporated to dryness and purified using a 10g silica Bond Elut cartridge eluting with CH₂Cl₂ and then ether to give the *title compound* (1.12g). LCMS RT=3.66min

viii) (5R)-3-[6-[4-(3-Aminophenyl)butoxy]hexyl]-5-(2,2-dimethyl-4H-1,3-benzodioxin-6-yl)-1,3-oxazolidin-2-one
(5R)-3-[6-[4-(3-Aminophenyl)butoxy]hexyl]-5-(2,2-dimethyl-4H-1,3-benzodioxin-6-yl)-1,3-oxazolidin-2-one (1.12g) was stirred with platinum oxide (120mg) in ethanol (10ml) and EtOAc (5ml) under hydrogen for 2h. The catalyst was removed by filtration through a pad of celite. The filtrate was evaporated to dryness to give the *title compound* (950mg). LCMS RT=2.51min.

ix) N-[3-[4-[(5R)-5-(2,2-Dimethyl-4H-1,3-benzodioxin-6-yl)-2-oxo-1,3-oxazolidin-3-yl]hexyl]oxy]butyl]phenyl]-N'-(4-fluorophenyl)urea

A solution of (5R)-3-[6-[4-(3-aminophenyl)butoxy]hexyl]-5-(2,2-dimethyl-4H-1,3-benzodioxin-6-yl)-1,3-oxazolidin-2-one (200mg) in CH₂Cl₂ (4ml) was reacted with 4-fluorophenylisocyanate (0.046ml) for 3h. Methanol (3ml) was added and the reaction stirred at 20°C for 60min. The reaction mixture was concentrated under reduced pressure to give the *title compound* (202mg). LCMS RT=4.02min.

x) N-(3-[4-[(2R)-2-(2,2-Dimethyl-4H-1,3-benzodioxin-6-yl)-2-hydroxyethyl]amino]hexyl]oxy]butyl]phenyl)-N'-(4-fluorophenyl)urea

A solution of N-[3-[4-[(5R)-5-(2,2-dimethyl-4H-1,3-benzodioxin-6-yl)-2-oxo-1,3-oxazolidin-3-yl]hexyl]oxy]butyl]phenyl]-N'-(4-fluorophenyl)urea (202mg) in THF (3ml) was stirred under nitrogen for 5min. Potassium trimethylsilanolate (204mg) was added and stirred under nitrogen at 65°C for 90min. The reaction mixture was diluted in water (5ml) and extracted into ethyl acetate (3x20ml), the resultant organic layers combined, dried (MgSO₄) and the solvent removed under reduced pressure and the residue purified on a Bond Elut Si cartridge (5g) eluting with 1%, 2%, 3%, 4% MeOH in CH₂Cl₂.

followed by 1%, 2%, 3% and 5% ammonia in MeOH in CH₂Cl₂ to give *the title compound* (138mg). ES+ve 608 (MH)⁺.

xi) N-(4-Fluorophenyl)-N'-[3-(4-[{6-((2R)-2-hydroxy-2-[4-hydroxy-3-

(hydroxymethyl)phenyl]ethyl}amino)hexyl]oxy}butyl]phenyl]urea acetate

N-(3-{4-[{6-((2R)-2-(2,2-Dimethyl-4H-1,3-benzodioxin-6-yl)-2-

hydroxyethyl]amino}hexyl]oxy]butyl]phenyl)-N'-(4-fluorophenyl)urea (138mg) was stirred with acetic acid (4ml) and water (2ml) at 70°C for 30min. The resultant mixture was evaporated to dryness and azeotroped with MeOH (2x4ml) to give the *title compound*

(157mg). LCMS RT=2.92min, ES+ve 568 (MH)⁺.

Example 2

N-(2,6-Dichlorophenyl)-N'-[3-(4-[{6-((2R)-2-hydroxy-2-[4-hydroxy-3-

(hydroxymethyl)phenyl]ethyl}amino)hexyl]oxy}butyl]phenyl]urea acetate

15

i) N-[3-[4-{6-[(5R)-5-(2,2-Dimethyl-4H-1,3-benzodioxin-6-yl)-2-oxo-1,3-oxazolidin-3-

y]hexyl]oxy}butyl]phenyl]-N'-(2,6-dichlorophenyl)urea

was similarly prepared according to Example 1ix. LCMS RT=4.02min

20

ii) N-(3-[4-{6-[(2R)-2-(2,2-Dimethyl-4H-1,3-benzodioxin-6-yl)-2-

hydroxyethyl]amino}hexyl]oxy]butyl]phenyl)-N'-(2,6-dichlorophenyl)urea

was similarly prepared according to Example 1x. LCMS RT=3.05min

25

iii) N-(2,6-Dichlorophenyl)-N'-[3-(4-[{6-((2R)-2-hydroxy-2-[4-hydroxy-3-

(hydroxymethyl)phenyl]ethyl}amino)hexyl]oxy}butyl]phenyl]urea acetate

was similarly prepared according to Example 1xi. LCMS RT=4.02min

Example 3

N-[3-(4-[{6-((2R)-2-Hydroxy-2-[4-hydroxy-3-(hydroxymethyl)phenyl]ethyl}-

30

amino)hexyl]oxy}butyl]phenyl]-N'-(4-methylphenyl)urea acetate

i) N-[3-[4-{6-[(5R)-5-(2,2-Dimethyl-4H-1,3-benzodioxin-6-yl)-2-oxo-1,3-oxazolidin-3-

y]hexyl]oxy}butyl]phenyl]-N'-(4-methylphenyl)urea

was similarly prepared according to Example 1ix. LCMS RT=4.09min

35

ii) N-(3-[4-[(6-[(2R)-2-(2,2-Dimethyl-4H-1,3-benzodioxin-6-yl)-2-hydroxyethyl]amino]hexyl]oxy]butyl]phenyl)-N'-(4-methylphenyl)urea
was similarly prepared according to Example 1x. LCMS RT=3.22min

5 iii) N-[3-(4-[(6-[(2R)-2-Hydroxy-2-[4-hydroxy-3-(hydroxymethyl)phenyl]ethyl]amino)hexyl]oxy]butyl]phenyl]-N'-(4-methylphenyl)urea acetate
was similarly prepared according to Example 1ix. LCMS RT=2.82min. ES+ve 564 (MH)⁺.

10 Example 4

([3-(4-[(6-[(2R)-2-Hydroxy-2-[4-hydroxy-3-(hydroxymethyl)phenyl]ethyl]amino)hexyl]oxy]butyl]anilino]carbonyl)amino)acetic acid acetate

15 i) Ethyl [(3-[4-[(6-[(5R)-5-(2,2-dimethyl-4H-1,3-benzodioxin-6-yl)-2-oxo-1,3-oxazolidin-3-yl]hexyl]oxy]butyl]anilino]carbonyl]amino]acetate
was similarly prepared according to Example 1ix. LCMS RT=3.72min

20 ii) [(3-[4-[(6-[(2R)-2-(2,2-Dimethyl-4H-1,3-benzodioxin-6-yl)-2-hydroxyethyl]amino]hexyl]oxy]butyl]anilino]carbonyl]amino]acetic acid
was similarly prepared according to Example 1x. LCMS RT=2.71min

25 iii) ([3-(4-[(6-[(2R)-2-Hydroxy-2-[4-hydroxy-3-(hydroxymethyl)phenyl]ethyl]amino)hexyl]oxy]butyl]anilino]carbonyl)amino)acetic acid acetate
was similarly prepared according to Example 1xi. LCMS RT=2.46min, ES+ve 532 (MH)⁺; ES-ve 530(M-H)⁻.

Example 5

30 N-[3-(4-[(6-[(2R)-2-Hydroxy-2-[4-hydroxy-3-(hydroxymethyl)phenyl]ethyl]amino)hexyl]oxy]butyl]phenyl]-N'-[3-(trifluoromethyl)phenyl]urea acetate

35 (i) N-[3-[4-[(6-[(5R)-5-(2,2-Dimethyl-4H-1,3-benzodioxin-6-yl)-2-oxo-1,3-oxazolidin-3-yl]hexyl]oxy]butyl]phenyl]-N'-[3-(trifluoromethyl)phenyl]urea
was similarly prepared according to Example 1ix. LCMS RT=4.20min.

(ii) N-(3-[4-[(6-[(2R)-2-(2,2-Dimethyl-4H-1,3-benzodioxin-6-yl)-2-hydroxyethyl]amino}hexyl]oxy]butyl}phenyl)-N'-(3-(trifluoromethyl)phenyl)urea

was similarly prepared according to Example 1x. LCMS RT=3.31 min. ES+ve 618 (MH)⁺: ES-ve 616 (M-H)⁻.

(iii) N-[3-(4-[(6-[(2R)-2-Hydroxy-2-[4-hydroxy-3-(hydroxymethyl)phenyl]ethyl]-amino)hexyl]oxy]butyl)phenyl]-N'-(3-(trifluoromethyl)phenyl)urea acetate

was similarly prepared according to Example 1xi. LCMS RT=2.99min. ES+ve 618(MH)⁺: ES-ve 616(M-H)⁻.

Example 6

N-(2,6-Dimethylphenyl)-N'-[3-(4-[(6-[(2R)-2-hydroxy-2-[4-hydroxy-3-(hydroxymethyl)phenyl]ethyl]amino)hexyl]oxy]butyl)phenyl]urea acetate

(i) N-[3-[4-[(6-[(5R)-5-(2,2-Dimethyl-4H-1,3-benzodioxin-6-yl)-2-oxo-1,3-oxazolidin-3-yl]hexyl]oxy]butyl]phenyl]-N'-(2,6-dimethylphenyl)urea

was similarly prepared according to Example 1ix. LCMS RT=3.96min.

(ii) N-(3-[4-[(6-[(2R)-2-(2,2-Dimethyl-4H-1,3-benzodioxin-6-yl)-2-hydroxyethyl]amino}hexyl]oxy]butyl}phenyl)-N'-(2,6-dimethylphenyl)urea

was similarly prepared according to Example 1x. LCMS RT=3.00min.

(iii) N-(2,6-Dimethylphenyl)-N'-[3-(4-[(6-[(2R)-2-hydroxy-2-[4-hydroxy-3-(hydroxymethyl)phenyl]ethyl]amino)hexyl]oxy]butyl)phenyl]urea acetate

was similarly prepared according to Example 1xi. LCMS RT=2.76min. ES+ve 578 (MH)⁺: ES-ve 576 (M-H)⁻.

Example 7

3-(4-[(6-[(2R)-2-Hydroxy-2-[4-hydroxy-3-(hydroxymethyl)phenyl]ethyl]-amino)hexyl]oxy]butyl)phenyl)-N'-phenylurea acetate

i) 2-Azido-1-(2,2-dimethyl-4H-1,3-benzodioxin-6-yl)ethanone

2-Bromo-1-(2,2-dimethyl-4H-1,3-benzodioxin-6-yl)ethanone (Glaxo DE 3513885, 1985)

(52g) in DMF (300ml) was treated with sodium azide (12.24g) and the mixture was

stirred for 2h at 20°C. The reaction mixture was diluted with EtOAc and washed with water and dried (MgSO_4). The solvent was removed under reduced pressure to give *the title compound* (39.11g). TSP+ve 248(MH^+).

5 ii) (1R)-2-Azido-1-(2,2-dimethyl-4H-1,3-benzodioxin-6-yl)ethanol
(R)-Tetrahydro-1-methyl-3,3-diphenyl-1H,3H-pyrrolo[1,2-c][1,3,2]oxazaborole solution in toluene (1M, 7.5ml) was added to THF (75ml) and the solution was diluted to 0°C. Borane-THF complex (1M solution in THF, 125ml) was added and the mixture was stirred under nitrogen for 15min. A solution of 2-azido-1-(2,2-dimethyl-4H-1,3-
10 benzodioxin-6-yl)ethanone (24.7g) in THF (250ml) was added dropwise over 1.5h at 5°C. The mixture was stirred for a further 1h and then cautiously treated with 2M HCl (100ml). The reaction mixture was extracted with ether and the organic layer was washed with 2M HCl, NaHCO_3 , brine, dried (MgSO_4). The solvent was removed by evaporation and the residue was chromatographed on a Biotage column eluting with
15 ether-petroleum ether(40-60°C) (1:9; 1:1) to give *the title compound* (16.99g). ES+ve 250 (MH^+).

iii) (1R)-2-Amino-1-(2,2-dimethyl-4H-1,3-benzodioxin-6-yl)ethanol
(1R)-2-Azido-1-(2,2-dimethyl-4H-1,3-benzodioxin-6-yl)ethanol (16.99g) was
20 hydrogenated over 10% Pd-C (1g) in EtOH (300ml). The catalyst was collected by filtration, and washed with EtOH. The combined washings were evaporated under reduced pressure and the residue was triturated in ether to give *the title compound* (5.86g). The mother liquors were chromatographed on a Biotage column eluting with toluene:EtOH:aqueous ammonia (85:14:1) to give a further batch of the title compound
25 (5.99g). LCMS RT=1.68 min, ES+ve 206 ($\text{MH}-\text{H}_2\text{O}^+$).

iv) 1-[4-[(6-Bromohexyl)oxy]but-1-ynyl]-3-nitrobenzene
A mixture of 1-iodo-3-nitrobenzene (3g), 1-bromo-6-(3-butynyloxy)hexane (3g) [Glaxo DE 3513885, 1985], bis(triphenylphosphine)palladium (II) chloride (0.421g), copper (I) iodide (0.114g) in DMF (10ml) and diisopropylethylamine (4ml) was stirred under nitrogen at 20 °C for 5h. The mixture was concentrated under reduced pressure and the residue was diluted in EtOAc and washed with 2M HCl, NaHCO_3 , brine and dried (MgSO_4). The solvent was removed by evaporation and the residue was chromatographed on a Biotage column eluting with ether:petroleum ether(40-60°C) (1:9) to give *the title compound* (4.12g). LCMS RT=4.14min

v) 3-{4-[(6-Bromohexyl)oxy]butyl}aniline

1-{4-[(6-Bromohexyl)oxy]but-1-ynyl}-3-nitrobenzene (4.12g) was hydrogenated over 10% Pd-C (0.3g) in EtOH (250ml). The catalyst was collected by filtration and washed with EtOH. The combined filtrate and washings were evaporated under reduced pressure to give *the title compound* (4.26g). LCMS RT=3.81min

5

vi) N-(3-{4-[(6-Bromohexyl)oxy]butyl}phenyl)-N'-phenylurea

A solution of 3-{4-[(6-bromohexyl)oxy]butyl}aniline (1g) in CH₂Cl₂ (10ml) was reacted with phenylisocyanate (0.4ml) for 2h. MeOH (5ml) was added and the mixture was stirred at 20°C overnight. The reaction mixture was concentrated under reduced pressure and the residue was purified on a Biotage column eluting with ether:petroleum ether(40-60°C) (15:85; 3:7; 1:1) to give *the title compound* (680mg). ES+ve 447/449 (MH)⁺.

10

vii) N-(3-{4-[(6-[(2R)-2-(2,2-Dimethyl-4H-1,3-benzodioxin-6-yl)-2-hydroxyethyl]amino}hexyl)oxy]butyl}phenyl)-N'-phenylurea

A mixture of N-(3-{4-[(6-bromohexyl)oxy]butyl}phenyl)-N'-phenylurea (350mg) and (1R)-2-amino-1-(2,2-dimethyl-4H-1,3-benzodioxin-6-yl)ethanol (349mg) in DMF (4ml) was stirred at 20°C overnight. The reaction mixture was diluted with CH₂Cl₂ and MeOH and applied to a silica Bond Elut cartridge (10g). The cartridge was eluted with 3% 2M anhydrous ammonia-MeOH in CH₂Cl₂. The major component was further purified by preparative TLC (4 plates; 20 × 20 cm) eluting with CH₂Cl₂:MeOH:aqueous ammonia (285:10:5) and extracting the silica with EtOAc:MeOH (2:1) to give *the title compound* (192 mg). LCMS RT=3.15min, ES+ve 590 (MH)⁺.

15

viii) 3-(4-[(6-[(2R)-2-Hydroxy-2-[4-hydroxy-3-

(hydroxymethyl)phenyl]ethyl]amino)hexyl]oxy]butyl}phenyl)-N'-phenylurea acetate

was similarly prepared according to Example 1xi. LCMS RT=2.77min, ES+ve 550 (MH)⁺; ES-ve 548 (M-H)⁻.

20

Example 8

N-Ethyl-N'-[3-(4-[(6-[(2R)-2-hydroxy-2-[4-hydroxy-3-

(hydroxymethyl)phenyl]ethyl]amino)hexyl]oxy]butyl}phenyl)urea acetate

25

i) N-(3-[4-[(6-Bromohexyl)oxy]butyl]phenyl)-N'-ethylurea

was similarly prepared according to Example 7vi. ES+ve 399/401 (MH)⁺.

5 ii) N-(3-[4-[(6-[(2R)-2-(2,2-Dimethyl-4H-1,3-benzodioxin-6-yl)-2-hydroxyethyl]amino]hexyl)oxy]butyl]phenyl)-N'-ethylurea

was prepared similarly according to Example 7vii. ES+ve 542 (MH)⁺.

10 iii) 3-(4-[(6-[(2R)-2-Hydroxy-2-[4-hydroxy-3-(hydroxymethyl)phenyl]ethyl]amino)hexyl]oxy]butyl]phenyl)-N'-ethylurea acetate

was prepared similarly according to Example 1xi. LCMS RT=2.44min, ES+ve 502 (MH)⁺

Example 9Ethyl {[3-(4-[(6-[(2R)-2-hydroxy-2-[4-hydroxy-3-(hydroxymethyl)phenyl]ethyl]amino)hexyl]oxy]butyl]anilino]carbonyl}amino}acetate acetatei) Ethyl {[3-(4-[(6-bromohexyl)oxy]butyl]anilino]carbonyl}amino}acetate

was prepared similarly according to Example 7vi. ES+ve 457/459 (MH)⁺.

20 ii) Ethyl {[3-(4-[(6-[(2R)-2-(2,2-dimethyl-4H-1,3-benzodioxin-6-yl)-2-hydroxyethyl]amino]hexyl)oxy]butyl]anilino]carbonyl}amino}acetate

was prepared similarly according to Example 7vii. ES+ve 600 (MH)⁺.

iii) Ethyl {[3-(4-[(6-[(2R)-2-hydroxy-2-[4-hydroxy-3-(hydroxymethyl)phenyl]ethyl]amino)hexyl]oxy]butyl]anilino]carbonyl}amino}acetate acetate

25 was prepared similarly according to Example 1xi. LCMS RT=2.66min ES+ve 560 (MH)⁺.

Example 10N-Cyclohexyl-N'-(3-(4-[(6-[(2R)-2-hydroxy-2-[4-hydroxy-3-(hydroxymethyl)phenyl]ethyl]amino)hexyl]oxy]butyl)phenyl)urea acetatei) N-(3-[4-[(6-Bromohexyl)oxy]butyl]phenyl)-N'-cyclohexylurea

35 was prepared similarly according to Example 7vi. ES+ve 453/455 (MH)⁺.

ii) N-Cyclohexyl-N'-(3-{4-[{6-[(2R)-2-(2,2-dimethyl-4H-1,3-benzodioxin-6-yl)-2-hydroxyethyl]amino}hexyl]oxy}butyl}phenyl)urea

was prepared similarly according to Example 7vii. ES+ve 596 (MH)⁺.

5

iii) N-Cyclohexyl-N'-(3-(4-{[6-((2R)-2-hydroxy-2-[4-hydroxy-3-(hydroxymethyl)phenyl]ethyl}amino)hexyl]oxy}butyl)phenyl)urea acetate

was prepared similarly according to Example 1xi. LCMS RT 2.62min ES+ve 556 (MH)⁺.

10

Example 11

N-[4-(4-{[6-((2R)-2-Hydroxy-2-[4-hydroxy-3-(hydroxymethyl)phenyl]ethyl}amino)hexyl]oxy}butyl)phenyl]-N'-phenylurea acetate

i) 1-{4-[6-Bromohexyl]oxy}but-1-ynyl}-4-nitrobenzene

was prepared using methods similar to those described in Example 7iv. tlc (silica)
R_f=0.42 (10% Et₂O/cyclohexane)

ii) 1-{4-[6-Bromohexyl]oxy}butyl}-4-nitrobenzene

was prepared using methods similar to those described in Example 7v. LCMS

20 RT=3.79min

iii) N-(4-{4-[6-Bromohexyl]oxy}butyl)phenyl)-N'-phenylurea

was prepared using methods similar to those described in Example 7vi. ES+ve 447/449 (MH)⁺.

25

iv) N-(4-{4-[{6-[(2R)-2-(2,2-Dimethyl-4H-1,3-benzodioxin-6-yl)-2-hydroxyethyl]amino}hexyl]oxy}butyl)phenyl)-N'-phenylurea

was prepared using methods similar to those described in Example 7vii. LCMS
RT=2.96min, ES+ve 590 (MH)⁺.

30

v) N-[4-(4-{[6-((2R)-2-Hydroxy-2-[4-hydroxy-3-(hydroxymethyl)phenyl]ethyl}amino)hexyl]oxy}butyl)phenyl]-N'-phenylurea acetate

was prepared using methods similar to those described in Example 1xi. LCMS
RT=2.71min, ES+ve 550 (MH)⁺.

35

Example 12

N-Ethyl-N'-[4-(4-[6-((2R)-2-hydroxy-2-[4-hydroxy-3-(hydroxymethyl)phenyl]ethyl}amino)hexyl]oxy}butyl]phenyl]urea acetate

5 i) N-(4-[4-[(6-Bromohexyl)oxy]butyl]phenyl)-N'-ethylurea

was prepared using methods similar to those described in Example 7vi. ES+ve 399/401 (MH)⁺.

10 ii) N-(4-[4-[(6-[(2R)-2-(2,2-Dimethyl-4H-1,3-benzodioxin-6-yl)-2-hydroxyethyl}amino}hexyl]oxy]butyl]phenyl)-N'-ethylurea

was prepared using methods similar to those described in Example 7vii. ES+ve 542 (MH)⁺.

15 iii) N-Ethyl-N'-[4-(4-[6-((2R)-2-hydroxy-2-[4-hydroxy-3-(hydroxymethyl)phenyl]ethyl}amino)hexyl]oxy}butyl]phenyl]urea acetate

was prepared using methods similar to those described in Example 1xi. LCMS RT=2.42min, ES+ve 502 (MH)⁺

Example 13

20 N-[3-(4-[6-((2R)-2-Hydroxy-2-[4-hydroxy-3-(hydroxymethyl)phenyl]ethyl}amino)hexyl]oxy}butyl]phenyl]-N'-pyridin-3-ylurea acetate

25 i) N-(3-Iodophenyl)-N'-pyridin-3-ylurea hydrochloride

3-iodophenyl isocyanate (250mg) and dried 3-aminopyridine (192mg) were dissolved in CH₂Cl₂ (4ml) and stirred under nitrogen overnight. MeOH (4ml) was added and the reaction mixture stirred for 1h. The solvents were removed *in vacuo*, the residue was dissolved in EtOAc and 2M HCl and stirred. The solid was removed by filtration, washed with water and air dried to give the *title compound* (500mg). LCMS RT=3.05 min.

30

ii) N-[3-[4-((6-[(5R)-5-(2,2-Dimethyl-4H-1,3-benzodioxin-6-yl)-2-oxo-1,3-oxazolidin-3-yl]hexyl]oxy)but-1-ynyl]phenyl]-N'-pyridin-3-ylurea

was prepared using methods similar to those described in Example 1vii.
LCMS RT=3.70min

35

iii) N-(3-{4-[{(2R)-2-(2,2-Dimethyl-4H-1,3-benzodioxin-6-yl)-2-hydroxyethyl]amino}hexyl}oxy]but-1-ynyl}phenyl)-N'-pyridin-3-ylurea

was prepared using methods similar to those described in Example 1x. LCMS RT=2.89min

5

iv) N-(3-{4-[{(2R)-2-(2,2-Dimethyl-4H-1,3-benzodioxin-6-yl)-2-hydroxyethyl]amino}hexyl}oxy]butyl}phenyl)-N'-pyridin-3-ylurea

N-(3-{4-[{(2R)-2-(2,2-Dimethyl-4H-1,3-benzodioxin-6-yl)-2-

hydroxyethyl]amino}hexyl}oxy]but-1-ynyl}phenyl)-N'-pyridin-3-ylurea (49mg) was

10 dissolved in EtOH (5ml) and EtOAc (5ml) and hydrogenated over 10% Pd/C (5mg). The catalyst was removed by filtration through celite, and the solvent removed *in vacuo*. The residue was then dissolved in MeOH and filtered through a cotton wool plug to yield the *title compound* (36mg). LCMS RT=2.93min.

15

v) N-[3-(4-[{6-({(2R)-2-Hydroxy-2-[4-hydroxy-3-}

(hydroxymethyl)phenyl]ethyl]amino}hexyl}oxy}butyl}phenyl]-N'-pyridin-3-ylurea acetate

was prepared using methods similar to those described in Example 1xi. LCMS

RT=2.62min, ES+ve 551 (MH)⁺.

20

Example 14

N-[3-(4-[{6-({(2R)-2-Hydroxy-2-[4-hydroxy-3-}

(hydroxymethyl)phenyl]ethyl]amino}hexyl}oxy}butyl}phenyl]-N'-pyrimidin-4-ylurea

i) N-(3-iodophenyl)-N'-pyrimidin-4-ylurea

25

A solution of 4-aminopyrimidine (95mg) in DMF (2ml) was cooled to 0°C and treated with a suspension of NaH (60% oil dispersion, 40mg) in DMF (1ml). The mixture was stirred under nitrogen for 45min at 0°C, before 3-iodophenyl isocyanate (245mg) was added slowly. The reaction mixture was allowed to warm up to room temperature, stirred for 3h and then water (10ml) was added. The reaction mixture was then

30

extracted with EtOAc (x3) and the combined organic layers washed with brine (x2), dried ($MgSO_4$) to yield the *title compound* (280mg). LCMS RT=3.40min.

ii) N-[3-{4-[{6-[(5R)-5-(2,2-Dimethyl-4H-1,3-benzodioxin-6-yl)-2-oxo-1,3-oxazolidin-3-yl]hexyl}oxy}but-1-ynyl}phenyl]-N'-pyrimidin-4-ylurea

35

was prepared using methods similar to those described in Example 1vii.

LCMS RT = 3.79min.

iii) N-[3-(4-[(2R)-2-Hydroxy-2-[4-hydroxy-3-
(hydroxymethyl)phenyl]ethyl}amino)hexyl]oxy}but-1-ynyl]phenyl]-N'-pyrimidin-4-ylurea

5 N-[3-[4-((6-[(5R)-5-(2,2-Dimethyl-4H-1,3-benzodioxin-6-yl)-2-oxo-1,3-oxazolidin-3-
yl]hexyl]oxy)but-1-ynyl]phenyl]-N'-pyrimidin-4-ylurea (109mg, 0.18mmol) was dissolved
in THF (5ml), treated with potassium trimethylsilanolate (68mg, 0.53mmol) and heated
to 65°C under nitrogen. After 5.5h, the reaction mixture was diluted with MeOH (10ml)
and the solvent removed *in vacuo*. The residue was dissolved in MeOH (10ml) and
10 applied to a 10g SCX cartridge preconditioned with MeOH and eluted with MeOH, 1%,
2% and 2.5% 2M ammonia in MeOH to give an oil. The oil was dissolved in CH₂Cl₂
(2ml) and MeOH (0.1ml) and applied to a 1g silica Bond Elut cartridge preconditioned
with and eluted with CH₂Cl₂, 1%, 2%, 3%, 5%, 8% and 10% 2M ammonia in
MeOH/CH₂Cl₂ to give the *title compound* (32mg). LCMS RT=2.79min.

15 iv) N-[3-(4-[(6-[(2R)-2-Hydroxy-2-[4-hydroxy-3-
(hydroxymethyl)phenyl]ethyl}amino)hexyl]oxy}butyl]phenyl]-N'-pyrimidin-4-ylurea
was prepared using methods similar to those described in Example 13iv. LCMS
RT=2.85min, ES+ve 552 (MH)⁺.

20 Example 15
N-[3,5-Bis(trifluoromethyl)phenyl]-N'-[3-(4-[(6-[(2R)-2-hydroxy-2-[4-hydroxy-3-
(hydroxymethyl)phenyl]ethyl}amino)hexyl]oxy}butyl]phenyl]urea acetate

25 i) N-[3,5-Bis(trifluoromethyl)phenyl]-N'-[3-[4-((6-[(5R)-5-(2,2-dimethyl-4H-1,3-
benzodioxin-6-yl)-2-oxo-1,3-oxazolidin-3-yl]hexyl]oxy)butyl]phenyl]urea
was prepared using methods similar to those described in Example 1ix. LCMS
RT=4.39min.

30 ii) N-[3,5-Bis(trifluoromethyl)phenyl]-N'-(3-[4-[(6-[(2R)-2-(2,2-dimethyl-4H-1,3-
benzodioxin-6-yl)-2-hydroxyethyl]amino)hexyl]oxy]butyl]phenyl]urea
was prepared using methods similar to those described in Example 1x. LCMS
RT=3.40min.

iii) N-[3,5-Bis(trifluoromethyl)phenyl]-N'-[3-(4-[{6-((2R)-2-hydroxy-2-[4-hydroxy-3-(hydroxymethyl)phenyl]ethyl}amino)hexyl]oxy}butyl]phenyl]urea acetate
was prepared using methods similar to those described in Example 1xi. LCMS RT=3.36min, ES-ve 684 (M-H)⁻.

5

Example 16

N-Cyclohexyl-N'-[3-(4-[{6-((2R)-2-hydroxy-2-[4-hydroxy-3-(hydroxymethyl)phenyl]ethyl}amino)hexyl]oxy}butyl]benzyl]urea acetate

- 10 i) (5R)-3-[6-{4-[3-(Aminomethyl)phenyl]but-3-ynyl}oxy]hexyl]-5-(2,2-dimethyl-4H-1,3-benzodioxin-6-yl)-1,3-oxazolidin-2-one
was prepared using methods similar to those described in Example 1vii. LCMS RT=2.77min.
- 15 ii) (5R)-3-(6-{4-[3-(Aminomethyl)phenyl]butoxy}hexyl)-5-(2,2-dimethyl-4H-1,3-benzodioxin-6-yl)-1,3-oxazolidin-2-one
was prepared using methods similar to those described in Example 1viii. LCMS RT=2.98min.
- 20 iii) N-Cyclohexyl-N'-[3-[4-{6-[(5R)-5-(2,2-dimethyl-4H-1,3-benzodioxin-6-yl)-2-oxo-1,3-oxazolidin-3-yl]hexyl}oxy]butyl]benzyl]urea
was prepared using methods similar to those described in Example 1ix. LCMS RT=3.93min.
- 25 iv) N-Cyclohexyl-N'-(3-{4-[6-[(2R)-2-(2,2-dimethyl-4H-1,3-benzodioxin-6-yl)-2-hydroxyethyl]amino}hexyl]oxy}butyl]benzyl)urea
was prepared using methods similar to those described in Example 1x. LCMS RT=2.92min.
- 30 v) N-Cyclohexyl-N'-[3-(4-[{6-((2R)-2-hydroxy-2-[4-hydroxy-3-(hydroxymethyl)phenyl]ethyl}amino)hexyl]oxy}butyl]benzyl]urea acetate
was prepared using methods similar to those described in Example 1xi. LCMS RT=2.69min, ES+ve 570 (MH)⁺.

Example 17

N-Ethyl-N'-[3-(4-[{6-((2R)-2-hydroxy-2-[4-hydroxy-3-(hydroxymethyl)phenyl]ethyl}amino)hexyl]oxy}butyl]benzyl]urea acetate

- 5 i) N-[3-[4-[(6-[(5R)-5-(2,2-Dimethyl-4H-1,3-benzodioxin-6-yl)-2-oxo-1,3-oxazolidin-3-yl]hexyl]oxy]butyl]benzyl]-N'-ethylurea

was prepared using methods similar to those described in Example 1ix.
LCMS RT=3.62min.

- 10 ii) N-(3-[4-[(6-[(2R)-2-(2,2-Dimethyl-4H-1,3-benzodioxin-6-yl)-2-hydroxyethyl]amino)hexyl]oxy]butyl]benzyl)-N'-ethylurea

was prepared using methods similar to those described in Example 1x. LCMS
RT=2.68min.

- 15 iii) N-Ethyl-N'-[3-(4-[{6-((2R)-2-hydroxy-2-[4-hydroxy-3-(hydroxymethyl)phenyl]ethyl}amino)hexyl]oxy}butyl]benzyl]urea acetate

was prepared using methods similar to those described in Example 1xi. LCMS
RT=2.55min, ES+ve 516 (MH)⁺.

20 Example 18

N-[3-(4-[{6-((2R)-2-Hydroxy-2-[4-hydroxy-3-(hydroxymethyl)phenyl]ethyl}amino)hexyl]oxy}butyl]benzyl]urea acetate

- 25 i) Ethyl N-[{3-[4-[(6-[(5R)-5-(2,2-dimethyl-4H-1,3-benzodioxin-6-yl)-2-oxo-1,3-oxazolidin-3-yl]hexyl]oxy]butyl]benzyl}amino]carbonyl]glycinate

was prepared using methods similar to those described in Example 1ix LCMS
RT=3.55min.

- ii) N-(3-[4-[(6-[(2R)-2-(2,2-Dimethyl-4H-1,3-benzodioxin-6-yl)-2-hydroxyethyl]amino)hexyl]oxy]butyl]benzyl)urea

30 was prepared using methods similar to those described in Example 1x. LCMS
RT=2.59min.

- iii) N-[3-(4-[{6-((2R)-2-Hydroxy-2-[4-hydroxy-3-(hydroxymethyl)phenyl]ethyl}amino)hexyl]oxy}butyl]benzyl]urea acetate

was prepared using methods similar to those described in Example 1xi. LCMS RT=2.66min, ES+ve 488 (MH)⁺.

Example 19

5 N-(4-Fluorophenyl)-N'-[3-(4-[{6-((2R)-2-hydroxy-2-[4-hydroxy-3-
(hydroxymethyl)phenyl]ethyl}amino)hexyl]oxy]butyl]benzyl]urea acetate

i) N-[3-{4-[(5R)-5-(2,2-Dimethyl-4H-1,3-benzodioxin-6-yl)-2-oxo-1,3-oxazolidin-3-
yl]hexyl]oxy]butyl]benzyl]-N'-(4-fluorophenyl)urea

10 was prepared using methods similar to those described in Example 1ix. LCMS RT=3.84min.

ii) N-(3-{4-[(6-[(2R)-2-(2,2-Dimethyl-4H-1,3-benzodioxin-6-yl)-2-
hydroxyethyl]amino}hexyl]oxy]butyl]benzyl)-N'-(4-fluorophenyl)urea

15 was prepared using methods similar to those described in Example 1x. LCMS RT=3.09min.

iii) N-(4-Fluorophenyl)-N'-[3-(4-[{6-((2R)-2-hydroxy-2-[4-hydroxy-3-
(hydroxymethyl)phenyl]ethyl}amino)hexyl]oxy]butyl]benzyl]urea acetate

20 was prepared using methods similar to those described in Example 1xi. LCMS RT=2.72min, ES+ve 582 (MH)⁺.

Example 20

25 N-(3-Chlorophenyl)-N'-[3-(4-[{6-((2R)-2-hydroxy-2-[4-hydroxy-3-
(hydroxymethyl)phenyl]ethyl}amino)hexyl]oxy]butyl]benzyl]urea acetate

i) N-(3-Chlorophenyl)-N'-{3-[4-[(6-[(5R)-5-(2,2-dimethyl-4H-1,3-benzodioxin-6-yl)-2-oxo-
1,3-oxazolidin-3-yl]hexyl]oxy]butyl]benzyl}urea

30 was prepared using methods similar to those described in Example 1ix. LCMS RT=4.00min.

ii) N-(3-Chlorophenyl)-N'-(3-{4-[(6-[(2R)-2-(2,2-dimethyl-4H-1,3-benzodioxin-6-yl)-2-
hydroxyethyl]amino}hexyl]oxy]butyl]benzyl)urea

35 was prepared using methods similar to those described in Example 1x. LCMS RT=3.05min.

iii) N-(3-Chlorophenyl)-N'-[3-(4-[{6-((2R)-2-hydroxy-2-[4-hydroxy-3-(hydroxymethyl)phenyl]ethyl}amino)hexyl]oxy}butyl]benzyl]urea acetate

was prepared using methods similar to those described in Example 1xi. LCMS
5 RT=2.96min, ES+ve 598, 600 (MH)⁺.

Example 21

N-Benzyl-N'-[3-(4-[{6-((2R)-2-hydroxy-2-[4-hydroxy-3-(hydroxymethyl)phenyl]ethyl}amino)hexyl]oxy}butyl]benzyl]urea acetate

i) N-Benzyl-N'-[3-[4-({6-[(5R)-5-(2,2-dimethyl-4H-1,3-benzodioxin-6-yl)-2-oxo-1,3-oxazolidin-3-yl]hexyl}oxy)butyl]benzyl]urea

was prepared using methods similar to those described in Example 1ix. LCMS
10 RT=3.75min.

ii) N-Benzyl-N'-[3-{4-[{6-[(2R)-2-(2,2-dimethyl-4H-1,3-benzodioxin-6-yl)-2-hydroxyethyl}amino}hexyl]oxy}butyl]benzyl]urea

was prepared using methods similar to those described in Example 1x. LCMS
15 RT=3.04min.

iii) N-Benzyl-N'-[3-(4-[{6-((2R)-2-hydroxy-2-[4-hydroxy-3-(hydroxymethyl)phenyl]ethyl}amino)hexyl]oxy}butyl]benzyl]urea acetate

as prepared using methods similar to those described in Example 1xi. LCMS
20 RT=2.65min, ES+ve 578 (MH)⁺.

Example 22

N-[(2-(4-[{6-((2R)-2-Hydroxy-2-[4-hydroxy-3-(hydroxymethyl)phenyl]ethyl}amino)hexyl]oxy}butyl)benzyl]amino]carbonyl)glycine acetate

i) Ethyl N-[(2-bromobenzyl)amino]carbonyl]glycinate

was prepared using methods similar to those described in Example 13i. LCMS
30 RT=2.84min.

ii) N-[(2-Bromobenzyl)amino]carbonyl]glycine

To a stirred solution of ethyl N-[(2-bromobenzyl)amino]carbonyl]glycinate (200mg) in THF (3ml) and MeOH (0.5ml) was added potassium trimethylsilanolate (81mg) and the reaction mixture stirred at room temperature for 3h. After this time, the solvent was removed *in vacuo* and the residue was dissolved in water (10ml) and extracted with EtOAc (3x25ml). The combined organic layers were dried (MgSO_4) and the solvent removed *in vacuo* to give the *title compound* (115mg). LCMS RT=2.64min.

5
5
10
15
20
25
30

iii) 1-[2-(4-{6-[5-(2,2-Dimethyl-4H-benzo[1,3]dioxin-6-yl)-2-oxo-oxazolidin-3-yl]-hexyloxy}-butyl)-benzyl]-3-(2-oxo-2-pyrrolidin-1-yl-ethyl)-urea

To a stirred solution of N-[(2-bromobenzyl)amino]carbonyl]glycine (175mg) and tetrakis(triphenylphosphine)palladium (0) (20mg) in pyrrolidine (2ml) under nitrogen, was added a solution of (5R)-3-[6-(but-3-nyloxy)hexyl]-5-(2,2-dimethyl-4H-1,3-benzodioxin-6-yl)-1,3-oxazolidin-2-one (example 1 vi) (222mg) in pyrrolidine (4ml) and the reaction mixture was heated to 80°C. After 5h, water (10ml) was added and extracted with EtOAc (3x25ml), the combined organic layers dried (MgSO_4) and the solvent removed *in vacuo*. The residue was dissolved in CH_2Cl_2 (8ml) and applied to a 10g silica Bond Elut cartridge preconditioned with CH_2Cl_2 and eluted with CH_2Cl_2 , EtOAc and 10% MeOH in CH_2Cl_2 to give the *title compound* (370mg). LCMS RT=3.46min.

iv) 1-[2-(4-{6-[5-(2,2-Dimethyl-4H-benzo[1,3]dioxin-6-yl)-2-oxo-oxazolidin-3-yl]-hexyloxy}-but-1-ynyl)-benzyl]-3-(2-oxo-2-pyrrolidin-1-yl-ethyl)-urea

was prepared using methods similar to those described in Example 1viii. LCMS RT=3.50min.

v) N-[(2-{4-[6-{[(2R)-2-(2,2-Dimethyl-4H-1,3-benzodioxin-6-yl)-2-hydroxyethyl]amino}hexyl]oxy}butyl)benzyl]amino]carbonyl]glycine

was prepared using methods similar to those described in Example 1x. LCMS RT=2.77min.

vi) N-[(2-(4-{[6-((2R)-2-Hydroxy-2-[4-hydroxy-3-(hydroxymethyl)phenyl]ethyl)amino}hexyl]oxy}butyl)benzyl]amino]carbonyl]glycine acetate

was prepared using methods similar to those described in Example 1xi. LCMS RT=2.57min, ES+ve 546 (MH)⁺.

Example 23

- 5 N-[2-[3-(4-[(2R)-2-Hydroxy-2-[4-hydroxy-3-
(hydroxymethyl)phenyl]ethyl]amino)hexyl]oxy]butyl]phenyl]ethyl]-N'-phenylurea acetate
- i) (5R)-3-[6-(4-[3-(2-Aminoethyl)phenyl]but-3-ynyl]oxy)hexyl]-5-(2,2-dimethyl-4H-1,3-
benzodioxin-6-yl)-1,3-oxazolidin-2-one
- 10 To a stirred solution of 2-(3-bromophenyl)ethanamine (500mg) and tetrakis
(triphenylphosphine)palladium (0) (60mg) in pyrrolidine (4ml) under nitrogen, was added
a solution of (5R)-3-[6-(but-3-ynyl)oxy]hexyl]-5-(2,2-dimethyl-4H-1,3-benzodioxin-6-yl)-
1,3-oxazolidin-2-one (example 1 vi) (912mg) in pyrrolidine (4ml) and the reaction
mixture was heated to 80°C. After 18h, water (10ml) was added and extracted with
- 15 EtOAc (3x25ml), the combined organic layers dried (MgSO_4) and the solvent removed
in vacuo. The residue was dissolved in CH_2Cl_2 (25ml) and applied to a Biotage
cartridge (40g) and eluted with CH_2Cl_2 , EtOAc and $\text{CH}_2\text{Cl}_2:\text{EtOH}:\text{aq NH}_3$ (100:8:1) to
give the *title compound* (668mg). LCMS RT=3.09min.
- 20 ii) (5R)-3-(6-[4-[3-(2-Aminoethyl)phenyl]butoxy]hexyl)-5-(2,2-dimethyl-4H-1,3-
benzodioxin-6-yl)-1,3-oxazolidin-2-one
was prepared using methods similar to those described in Example 1viii. LCMS
RT=3.14min.
- 25 iii) N-(2-[3-[4-[(6-[(5R)-5-(2,2-Dimethyl-4H-1,3-benzodioxin-6-yl)-2-oxo-1,3-oxazolidin-
3-yl]hexyl]oxy]butyl]phenyl]ethyl)-N'-phenylurea
was prepared using methods similar to those described in Example 1ix. LCMS
RT=3.98min.
- 30 iv) N-[2-(3-[4-[(6-[(2R)-2-(2,2-Dimethyl-4H-1,3-benzodioxin-6-yl)-2-
hydroxyethyl]amino]hexyl]oxy]butyl]phenyl]ethyl]-N'-phenylurea
was prepared using methods similar to those described in Example 1x. LCMS
RT=3.27min.

v) N-[2-[3-(4-[6-((2R)-2-Hydroxy-2-[4-hydroxy-3-(hydroxymethyl)phenyl]ethyl}amino)hexyl]oxy]butyl]phenyl]ethyl}-N'-phenylurea acetate
was prepared using methods similar to those described in Example 1xi. LCMS
RT=2.98min, ES+ve 578 (MH)⁺.

5

Example 24

N-[3-(4-[6-((2R)-2-Hydroxy-2-[4-hydroxy-3-(hydroxymethyl)phenyl]ethyl}amino)hexyl]oxy]butyl]phenyl]urea acetate

10

i) N-(3-Iodophenyl)urea

A suspension of sodium cyanate (6.5g) in water (50ml) was slowly added to a solution of 3-iodoaniline (6ml) in 50% aqueous acetic acid (40ml) and the mixture was stirred for 3h at 20°C. Water (300ml) was added and the solid was collected by filtration. The solid was washed with water, air-dried and triturated in ether to give *the title compound* (11.93g). ES+ve 263 (MH)⁺.

15

ii) N-(3-[4-[(6-Bromohexyl)oxy]but-1-ynyl]phenyl)urea

A mixture of N-(3-iodophenyl)urea (1.05g), 6-bromohexyl but-3-ynyl ether (1g) [Glaxo DE3513885], bis(triphenylphosphine)palladium (II) chloride (140mg), copper (I) iodide (38mg) in DMF (5ml) and diisopropylethylamine (2ml) was stirred under nitrogen at 20°C for 15h. The mixture was diluted with EtOAc and washed with 2M HCl, NaHCO₃, brine and dried (MgSO₄). The solvent was removed by evaporation and the residue was chromatographed on a Biotage column eluting with CH₂Cl₂ and MeOH:CH₂Cl₂ (1:49) to give *the title compound* (656mg). ES+ve 367/369 (MH)⁺.

25

iii) N-(3-[4-[(6-Bromohexyl)oxy]butyl]phenyl)urea

N-(3-[4-[(6-bromohexyl)oxy]but-1-ynyl]phenyl)urea (650mg) was hydrogenated over platinum oxide (70mg) in EtOAc (75ml) for 16h. The catalyst was collected by filtration, washed with EtOAc and the combined filtrate and washings were evaporated under reduced pressure to give mainly *the title compound* but contaminated with some partially hydrogenated product. ES+ve 369/371/373 (MH)⁺.

iv) N-(3-{4-[(6-[(2R)-2-(2,2-Dimethyl-4H-1,3-benzodioxin-6-yl)-2-hydroxyethyl]amino)hexyl]oxy]butyl}phenyl)urea

The above product (680mg) was reacted with (1R)-2-amino-1-(2,2-dimethyl-4H-1,3-benzodioxin-6-yl)ethanol (470mg) in DMF (4ml) overnight. The mixture was diluted with EtOAc and washed with water, brine, dried ($MgSO_4$). The solution was evaporated and the residue was purified on a Biotage column eluting with 2M anhydrous ammonia in MeOH:CH₂Cl₂ (1:24) to give mainly *the title compound* contaminated with some unsaturated material (400mg). ES+ve 512/514 (MH)⁺.

5 iv) N-[3-(4-[(2R)-2-Hydroxy-2-[4-hydroxy-3-(hydroxymethyl)phenyl]ethyl]amino)hexyl]oxy}butyl]phenyl]urea acetate
10 The above mixture was hydrogenated over platinum oxide (85mg) in EtOH (75ml) for 3h. The catalyst was collected by filtration and washed with EtOH. The combined filtrate and washings were evaporated under reduced pressure to give *the title compound* (350mg). ES+ve 514 (MH)⁺.

15 Example 25

N-[3-(3-[(2R)-2-Hydroxy-2-[4-hydroxy-3-(hydroxymethyl)phenyl]ethyl]amino)heptyl]oxy}propyl]phenyl]urea acetate

i) 7-bromoheptyl prop-2-ynyl ether

was prepared using methods similar to those described in Example 1 v.

20 LCMS RT=3.63min.

ii) N-(3-[(7-Bromoheptyl)oxy]prop-1-ynyl)phenyl)urea and N-(3-[(7-iodoheptyl)oxy]prop-1-ynyl)phenyl)urea

A mixture of *N*-(3-iodophenyl)urea (524mg), 7-bromoheptyl prop-2-ynyl ether (490mg), bis(triphenylphosphine)palladium (II) chloride (70mg), copper (I) iodide (19mg) and *N,N*-diisopropylethylamine (1.05ml) in DMF (5ml) was stirred under nitrogen at 20°C for 18h. The mixture was then diluted in EtOAc and washed with 2M HCl, NaHCO₃, brine and dried ($MgSO_4$). The solution was concentrated in vacuo and the residue was purified by chromatography (Biotage, 40g) eluting with CH₂Cl₂-MeOH (99:1) to give the *title compounds* (421mg) as a 55:45 ratio respectively. LCMS RT=3.42 and 3.55 min.

iii) N-(3-[(7-[(2R)-2-(2,2-Dimethyl-4H-1,3-benzodioxin-6-yl)-2-hydroxyethyl]amino)heptyl]oxy}prop-1-ynyl)phenyl)urea

The above mixture (421mg) was reacted with (1*R*)-2-amino-1-(2,2-dimethyl-4*H*-1,3-benzodioxin-6-yl)ethanol (514mg) in DMF (5ml) for 18h. The mixture was diluted with EtOAc and washed with water, brine and dried (MgSO_4). The solution was concentrated in vacuo and the residue was purified by chromatography (Biotage, 40g) eluting with CH_2Cl_2 and then CH_2Cl_2 -MeOH: 2M NH_3 /MeOH (97:2:1), (95:3:2), (95:4:1) and (90:6:4) to give the *title compound* (355mg). LCMS RT=2.62min

iv) *N*-(3-{3-[(2*R*)-2-(2,2-Dimethyl-4*H*-1,3-benzodioxin-6-yl)-2-hydroxyethyl]amino}heptyl)oxy]propyl}phenyl)urea

10 Prepared using methods similar to those described in Example 1 viii)
LCMS RT=2.60min

v) *N*-[3-(3-{[(2*R*)-2-Hydroxy-2-[4-hydroxy-3-(hydroxymethyl)phenyl]ethyl}amino)heptyl]oxy]propyl}phenyl]urea acetate

15 Prepared using methods similar to those described in Example 1 xi)
LCMS RT= 2.37min, ES+ve 474 (MH^+)[†]

Example 26

***N*-[3-(5-[(2*R*)-2-Hydroxy-2-[4-hydroxy-3-(hydroxymethyl)phenyl]ethyl}amino)penty]oxy]pentyl}phenyl]urea acetate**

i) *N*-(3-{5-[(5-Bromopentyl)oxy]pent-1-ynyl}phenyl)urea and

N-(3-{5-[(5-iodopentyl)oxy]pent-1-ynyl}phenyl)urea

Prepared using methods similar to those described in Example 25i)

Product ratio= 66:34. LCMS RT=3.38 and 3.50min.

25

ii) *N*-(3-{5-[(2*R*)-2-(2,2-Dimethyl-4*H*-1,3-benzodioxin-6-yl)-2-hydroxyethyl]amino}pentyl)oxy]pent-1-ynyl}phenyl)urea

Prepared using methods similar to those described in Example 25 ii)

LCMS RT=2.52min.

30

iii) *N*-(3-{5-[(2*R*)-2-(2,2-Dimethyl-4*H*-1,3-benzodioxin-6-yl)-2-hydroxyethyl]amino}pentyl)oxy]pentyl}phenyl)urea

Prepared using methods similar to those described in Example 1 viii)

LCMS RT=2.56min

iv) N-[3-(5-[(2R)-2-Hydroxy-2-[4-hydroxy-3-(hydroxymethyl)phenyl]ethyl}amino)pentyl]oxy}pentyl]phenyl]urea acetate

5 Prepared using methods similar to those described in Example 1 xi)

LCMS RT=2.39min, ES+ve 474 (MH)⁺

Example 27

N-[3-(5-[(2R)-2-Hydroxy-2-[4-hydroxy-3-

10 (hydroxymethyl)phenyl]ethyl}amino)hexyl]oxy}pentyl]phenyl]urea acetate

i) N-(3-[5-[(6-Bromohexyl)oxy]pent-1-ynyl]phenyl)urea and N-(3-[5-[(6-iodohexyl)oxy]pent-1-ynyl]phenyl)urea

Prepared using methods similar to those described in Example 25 i)

15 Product ratio=66:34. LCMS RT=3.64 and 3.76min.

ii) N-(3-[5-[(2R)-2-(2,2-Dimethyl-4H-1,3-benzodioxin-6-yl)-2-hydroxyethyl]amino}hexyl]oxy]pent-1-ynyl]phenyl)urea

Prepared using methods similar to those described in Example 25 ii)

20

iii) N-(3-[5-[(2R)-2-(2,2-Dimethyl-4H-1,3-benzodioxin-6-yl)-2-hydroxyethyl]amino}hexyl]oxy]pentyl]phenyl)urea

Prepared using methods similar to those described in Example 1 viii)

LCMS RT=2.71min

25

iv) N-[3-(5-[(2R)-2-Hydroxy-2-[4-hydroxy-3-(hydroxymethyl)phenyl]ethyl}amino)hexyl]oxy}pentyl]phenyl]urea acetate

Prepared using methods similar to those described in Example 1 xi)

LCMS RT=2.53min, ES+ve 488 (MH)⁺

30

Example 28

N-[3-(4-[(2R)-2-Hydroxy-2-[4-hydroxy-3-(hydroxymethyl)phenyl]ethyl]amino)hexyl]oxy]butyl)-5-(trifluoromethyl)phenyl]urea acetate

5 i) N-[3-Bromo-5-(trifluoromethyl)phenyl]urea

was prepared using methods similar to those described in Example 24i)

LCMS RT=3.20min

10 ii) N-[3-{4-[(6-Bromohexyl)oxy]but-1-ynyl}-5-(trifluoromethyl)phenyl]urea

was prepared using methods similar to those described in Example 25i)

LCMS RT=3.84min

15 iii) N-[3-{4-[(6-[(2R)-2-(2,2-Dimethyl-4H-1,3-benzodioxin-6-yl)-2-hydroxyethyl]amino}hexyl]oxy]but-1-ynyl}-5-(trifluoromethyl)phenyl]urea

was prepared using methods similar to those described in Example 25ii)

LCMS RT=2.86min

20 iv) N-[3-{4-[(6-[(2R)-2-(2,2-Dimethyl-4H-1,3-benzodioxin-6-yl)-2-hydroxyethyl]amino}hexyl]oxy]butyl}-5-(trifluoromethyl)phenyl]urea

was prepared using methods similar to those described in Example 1viii)

LCMS RT=2.75min

25 v) N-[3-(4-[(2R)-2-Hydroxy-2-[4-hydroxy-3-

(hydroxymethyl)phenyl]ethyl]amino)hexyl]oxy]butyl)-5-(trifluoromethyl)phenyl]urea

acetate

was prepared using methods similar to those described in Example 1xi)

LCMS RT=2.62min, ES+ve 542 (MH)⁺.

Example 29

30 N-[3-(4-[(2R)-2-Hydroxy-2-[4-hydroxy-3-

(hydroxymethyl)phenyl]ethyl]amino)hexyl]oxy]butyl)-5-methylphenyl]urea acetate

i) (5R)-5-(2,2-Dimethyl-4H-1,3-benzodioxin-6-yl)-3-(6-[4-(3-methyl-5-nitrophenyl)but-3-ynyl]oxy)hexyl)-1,3-oxazolidin-2-one

was prepared using methods similar to those described in Example 1vii. LCMS
RT=3.94min.

5

ii) (5R)-3-{6-[4-(3-Amino-5-methylphenyl)butoxy]hexyl}-5-(2,2-dimethyl-4H-1,3-benzodioxin-6-yl)-1,3-oxazolidin-2-one

was prepared using methods similar to those described in Example 1viii. LCMS
RT=3.58min.

10

iii) N-[3-{4-[(6-[(5R)-5-(2,2-Dimethyl-4H-1,3-benzodioxin-6-yl)-2-oxo-1,3-oxazolidin-3-yl]hexyl]oxy}butyl]-5-methylphenyl]urea

was prepared using methods similar to those described in Example 24i. LCMS
RT=3.57min.

15

iv) N-(3-{4-[(6-[(2R)-2-(2,2-Dimethyl-4H-1,3-benzodioxin-6-yl)-2-hydroxyethyl]amino]hexyl]oxy}butyl)-5-methylphenyl]urea

was prepared using methods similar to those described in Example 1x. LCMS
RT=2.79min.

20

v) N-[3-(4-[(6-[(2R)-2-Hydroxy-2-[4-hydroxy-3-(hydroxymethyl)phenyl]ethyl]amino]hexyl]oxy}butyl)-5-methylphenyl]urea acetate

was prepared using methods similar to those described in Example 1xi. LCMS
RT=2.55min. ES+ve 488 (MH)⁺.

25

Example 30

5-(4-[(6-[(2R)-2-Hydroxy-2-[4-hydroxy-3-(hydroxymethyl)phenyl]ethyl]amino]hexyl]oxy}butyl)-1,3-dihydro-2H-benzimidazol-2-one acetate

30

i) N-Benzyl-4-iodo-2-nitroaniline

A mixture of benzylamine (0.84ml), diisopropylethylamine (1.33ml) and 1-fluoro-4-iodo-2-nitrobenzene (1.02g) in dichloromethane (10ml) was stirred for 15h at 20°C. The

mixture was diluted with dichloromethane and washed with aqueous 2M HCl, NaHCO₃ solution, dried (MgSO₄) and filtered. The filtrate was evaporated to give *the title compound* (1.25g) LCMS RT=4.01min

5 ii) (5R)-3-[6-(4-(Benzylamino)-3-nitrophenyl]but-3-ynyl}oxy)hexyl]-5-(2,2-dimethyl-4H-1,3-benzodioxin-6-yl)-1,3-oxazolidin-2-one

was prepared using methods similar to those described in Example 1vii)
LCMS RT=3.62min

10 iii) (5R)-3-[6-(4-(3,4-Diaminophenyl)butoxy]hexyl]-5-(2,2-dimethyl-4H-1,3-benzodioxin-6-yl)-1,3-oxazolidin-2-one

was prepared using methods similar to those described in Example 1viii)
LCMS RT=3.21min

15 iv) 5-[4-(6-[(5R)-5-(2,2-Dimethyl-4H-1,3-benzodioxin-6-yl)-2-oxo-1,3-oxazolidin-3-yl]hexyl}oxy)butyl]-1,3-dihydro-2H-benzimidazol-2-one

A solution of (5R)-3-[6-[4-(3,4-diaminophenyl)butoxy]hexyl]-5-(2,2-dimethyl-4H-1,3-benzodioxin-6-yl)-1,3-oxazolidin-2-one (176mg) and carbonyldiimidazole (206mg) in THF (5ml) was stirred at 20°C for 16h. The mixture was purified on a 10g Bond Elut cartridge
20 eluting with dichloromethane-MeOH (1:0 to 19:1) to give *the title compound* (71mg)
LCMS RT=3.62min.

v) 5-(4-[(2R)-2-Hydroxy-2-[4-hydroxy-3-(hydroxymethyl)phenyl]ethyl}amino)hexyl}oxy}butyl)-1,3-dihydro-2H-benzimidazol-2-one

25 was prepared using methods similar to those described in Example 14iii) LCMS RT=2.44min.

vi) 5-(4-[(2R)-2-Hydroxy-2-[4-hydroxy-3-(hydroxymethyl)phenyl]ethyl}amino)hexyl}oxy}butyl)-1,3-dihydro-2H-benzimidazol-2-one

30 acetate

was prepared using methods similar to those described in Example 1xi)
LCMS RT=2.44min, ES+ve 472 (MH)⁺.

Example 31

N-Benzoyl-N'-[3-(4-[{6-((2R)-2-hydroxy-2-[4-hydroxy-3-(hydroxymethyl)phenyl]ethyl}amino)hexyl]oxy]butyl]phenyl]urea

5 i) N-Benzoyl-N'-(3-iodophenyl)urea

3-iodoaniline (0.5g) in dichloromethane (5ml) was treated with benzoyl isocyanate (0.34g) in dichloromethane (7ml) and the mixture was stirred at 20 °C for 15h. MeOH (10ml) was added and after 4h the solid was collected by filtration and dried to give *the title compound* (0.59g) LCMS RT=3.76min

10

ii) N-Benzoyl-N'-(3-[4-[(6-bromohexyl)oxy]but-1-ynyl]phenyl)urea

was prepared using methods similar to those described in Example 1vii)
LCMS RT=4.11min

15 iii) N-Benzoyl-N'-(3-[4-[(6-[(2R)-2-(2,2-dimethyl-4H-1,3-benzodioxin-6-yl)-2-hydroxyethyl]amino]hexyl]oxy]but-1-ynyl]phenyl)urea

was prepared using methods similar to those described in Example 7vii)
LCMS RT=3.17min

20 iv) N-Benzoyl-N'-[3-(4-[{6-((2R)-2-hydroxy-2-[4-hydroxy-3-(hydroxymethyl)phenyl]ethyl}amino)hexyl]oxy]butyl]phenyl]urea

was prepared using methods similar to those described in Example 14iii)
LCMS RT=2.93min, ES+ve 578 (MH)⁺.

25 Example 32

N-[2-(4-[{6-((2R)-2-Hydroxy-2-[4-hydroxy-3-(hydroxymethyl)phenyl]ethyl}amino)hexyl]oxy]butyl]phenyl]-N'-phenylurea acetate

i) N-(2-iodophenyl)-N'-phenylurea

30 was prepared using methods similar to those described in Example 31i)
LCMS RT=3.61min

ii) N-(2-[4-[(6-Bromohexyl)oxy]but-1-ynyl]phenyl)-N'-phenylurea

was prepared using methods similar to those described in Example 1vii)

LCMS RT=3.61min

5 iii) N-(2-{4-[(2R)-2-(2,2-Dimethyl-4H-1,3-benzodioxin-6-yl)-2-hydroxyethyl]amino}hexyl)oxy]but-1-ynyl]phenyl)-N'-phenylurea

was prepared using methods similar to those described in Example 7vii)

LCMS RT=2.83min

10 iv) N-(2-{4-[(2R)-2-(2,2-Dimethyl-4H-1,3-benzodioxin-6-yl)-2-hydroxyethyl]amino}hexyl)oxy]butyl]phenyl)-N'-phenylurea

was prepared using methods similar to those described in Example 1viii)

LCMS RT=2.79min

15 v) N-[2-(4-{[6-((2R)-2-hydroxy-2-[4-hydroxy-3-(hydroxymethyl)phenyl]ethyl)amino}hexyl)oxy]butyl]phenyl]-N'-phenylurea acetate

was prepared using methods similar to those described in Example 1xi)

LCMS RT=2.63min, ES+ve 550 (MH)⁺.

Example 33

N-[3-(4-{[6-((2R)-2-Hydroxy-2-[4-hydroxy-3-

20 (hydroxymethyl)phenyl]ethyl)amino}hexyl)oxy]butyl]phenyl]-N'-(3-hydroxyphenyl)urea

i) N-(3-Hydroxyphenyl)-N'-(3-iodophenyl)urea

was prepared using methods similar to those described in Example 31i)

LCMS RT=3.39min

25

ii) N-[3-[4-((6-[(5R)-5-(2,2-Dimethyl-4H-1,3-benzodioxin-6-yl)-2-oxo-1,3-oxazolidin-3-yl]hexyl)oxy]but-1-ynyl]phenyl]-N'-(3-hydroxyphenyl)urea

was prepared using methods similar to those described in Example 1vii)

LCMS RT=3.70min

30

iii) N-[3-[4-((6-[(5R)-5-(2,2-Dimethyl-4H-1,3-benzodioxin-6-yl)-2-oxo-1,3-oxazolidin-3-yl]hexyl)oxy]butyl]phenyl]-N'-(3-hydroxyphenyl)urea

was prepared using methods similar to those described in Example 1viii)

LCMS RT=3.73min

iv) N-[3-(4-{[6-((2R)-2-Hydroxy-2-[4-hydroxy-3-
(hydroxymethyl)phenyl]ethyl}amino)hexyl]oxy}butyl]phenyl]-N'-(3-hydroxyphenyl)urea

5 was prepared using methods similar to those described in Example 14iii)

LCMS RT=2.59min, ES+ve 566 (MH)⁺.

Example 34

I){[3-(4-{[6-((2R)-2-Hydroxy-2-[4-hydroxy-3-
10 (hydroxymethyl)phenyl]ethyl}amino)hexyl]oxy}butyl]phenyl]amino}carbonyl]amino](oxo)
acetic acid

i) N-[3-[4-{[6-[(5R)-5-(2,2-Dimethyl-4H-1,3-benzodioxin-6-yl)-2-oxo-1,3-oxazolidin-3-
yl]hexyl]oxy)but-1-ynyl]phenyl]urea

15 was prepared using methods similar to those described in Example 1vii). LCMS
RT=3.46min.

ii) N-[3-[4-{[6-[(5R)-5-(2,2-Dimethyl-4H-1,3-benzodioxin-6-yl)-2-oxo-1,3-oxazolidin-3-
yl]hexyl]oxy)butyl]phenyl]urea

20 was prepared using methods similar to those described in Example 1viii). LCMS
RT=3.37min.

iii) 1-[3-[4-{[6-[(5R)-5-(2,2-Dimethyl-4H-1,3-benzodioxin-6-yl)-2-oxo-1,3-oxazolidin-3-
yl]hexyl]oxy)butyl]phenyl]imidazolidine-2,4,5-trione

25 N-[3-[4-{[6-[(5R)-5-(2,2-Dimethyl-4H-1,3-benzodioxin-6-yl)-2-oxo-1,3-oxazolidin-3-
yl]hexyl]oxy)butyl]phenyl]urea (0.52g) was dissolved in absolute ethanol (25ml) and
treated with diethyl oxalate (0.65ml) and then sodium (0.07g) in ethanol (7ml). After
stirring for 2 h another portion of sodium (0.023g) in ethanol (2.3ml) was added. After a
further hour the reaction mixture was evaporated under reduced pressure and
30 partitioned between pH 6.4 phosphate buffer and EtOAc. The organic layer was
separated off and the aqueous phase extracted twice more with EtOAc. The combined
extracts were dried ($MgSO_4$), evaporated under reduced pressure and purified by

chromatography (Biotage, 40g) eluting with EtOAc-cyclohexane (1:1) to give *the title compound* (0.277g) LCMS RT=3.37min.

iv) ([(3-[4-[(6-[(2R)-2-(2,2-Dimethyl-4H-1,3-benzodioxin-6-yl)-2-hydroxyethyl]amino]hexyl)oxy]butyl]phenyl]amino]carbonyl)amino](oxo)acetic acid
5 was prepared using methods similar to those described in Example 1x). LCMS RT=2.89min.

v) [([(3-[4-[(6-[(2R)-2-Hydroxy-2-[4-hydroxy-3-(hydroxymethyl)phenyl]ethyl]amino)hexyl]oxy]butyl)phenyl]amino]carbonyl)amino](oxo)acetic acid
10 was prepared using methods similar to those described in Example 1xi). LCMS RT=2.89min, ES+ve 546 (MH)⁺.

15 Example 35
N-[3-(4-[(6-[(2R)-2-[3-(Formylamino)-4-hydroxyphenyl]-2-hydroxyethyl]amino)hexyl]oxy]butyl]phenyl]urea

i) N-[3-(4-[(6-[(2R)-2-[4-(benzyloxy)-3-(formylamino)phenyl]-2-hydroxyethyl]amino)hexyl]oxy]but-1-ynyl]phenyl]urea
20 A solution of 5-((1*R*)-2-{benzyl[6-(but-3-nyloxy)hexyl]amino}-1-hydroxyethyl)-2-(benzyloxy)phenylformamide (WO 0276933) (0.67 g) and 3-iodophenylurea (0.41 g) in acetonitrile (5 ml) and triethylamine (2.2 ml) was treated with bis(triphenylphosphine) palladium dichloride (109 mg) and copper (I) iodide (54 mg) and the mixture was stirred
25 under nitrogen for 4.5 h. The solvents were removed under reduced pressure and the residue was chromatographed on a Bond Elut silica cartridge (10 g) eluting with ethyl acetate-cyclohexane (1:4) to neat ethyl acetate and then on a Biotage cartridge (12 g) eluting with neat ethyl acetate to give *the title compound* (239 mg) LCMS RT = 2.69 min.

30 ii) N-[3-(4-[(6-[(2R)-2-[3-(Formylamino)-4-hydroxyphenyl]-2-hydroxyethyl]amino)hexyl]oxy]butyl]phenyl]urea

A solution of *N*-[3-(4-[{6-(benzyl{(2*R*)-2-[4-(benzyloxy)-3-(formylamino)phenyl]-2-hydroxyethyl}amino)hexyl]oxy}but-1-ynyl)phenyl]urea (232 mg) was hydrogenated over 10% palladium on carbon (35 mg) and palladium hydroxide (35 mg) in ethanol (10 ml) at a pressure of 100 psi overnight. The catalysts were removed by filtration and washed 5 with ethanol. The combined filtrate and washings were evaporated under reduced pressure and the residue was purified by mass directed HPLC to give the title compound as the trifluoroacetate salt. The free base was obtained by ion exchange chromatography on an SCX-2 cartridge (10 g) eluting first with methanol and then with 2% aqueous ammonia in methanol to give *the title compound* (77.7 mg). LCMS RT = 10 2.18 min, ES+ve *m/z* 487 (*MH*)⁺.

Example 36

N-[3-(4-[{6-(({2*R*)-2-[3-(Formylamino)-4-hydroxyphenyl]-2-hydroxyethyl}amino)hexyl]oxy}butyl)phenyl]-*N'*-phenylurea

15 *N*-[3-(4-[{6-(benzyl{(2*R*)-2-[4-(benzyloxy)-3-(formylamino)phenyl]-2-hydroxyethyl}amino)hexyl]oxy}but-1-ynyl)phenyl]-*N'*-phenylurea

Prepared using methods similar to those described in Example 35 i)
LCMS RT = 2.93 min.

20 ii) *N*-[3-(4-[{6-(({2*R*)-2-[3-(Formylamino)-4-hydroxyphenyl]-2-hydroxyethyl}amino)hexyl]oxy}butyl)phenyl]-*N'*-phenylurea

Prepared using methods similar to those described in Example 35 ii)
LCMS RT = 2.59 min, ES+ve *m/z* 563 (*MH*)⁺

25 Example 37

N-[3-(4-[{6-(({2*R*)-2-[3-(Formylamino)-4-hydroxyphenyl]-2-hydroxyethyl}amino)hexyl]oxy}butyl)phenyl]-*N'*-pyridin-3-ylurea with (2*E*)-but-2-enedioic acid (1:1)

30 i) *N*-[3-(4-[{6-(Benzyl{(2*R*)-2-[4-(benzyloxy)-3-(formylamino)phenyl]-2-hydroxyethyl}amino)hexyl]oxy}but-1-ynyl)phenyl]-*N'*-pyridin-3-ylurea

Prepared using methods similar to those described in Example 35 i)

LCMS RT = 3.15 min.

ii) N-[3-(4-[(6-((2R)-2-[3-(Formylamino)-4-hydroxyphenyl]-2-hydroxyethyl)amino)hexyl]oxy]butyl]phenyl]-N'-pyridin-3-ylurea with (2E)-but-2-enedioic acid (1:1)

Prepared using methods similar to those described in Example 35 ii)

LCMS RT = 2.42 min, ES+ve *m/z* 564 (MH)⁺

10

BIOLOGICAL ACTIVITY


The potencies of the aforementioned compounds were determined using frog melanophores transfected with the human beta 2 adrenoreceptor. The cells were incubated with melatonin to induce pigment aggregation. Pigment dispersal was induced by compounds acting on the human beta 2 adrenoreceptor. The beta 2 agonist activity of test compounds was assessed by their ability to induce a change in light transmittance across a melanophore monolayer (a consequence of pigment dispersal). At the human beta 2 adrenoreceptor, compounds of examples 1-37 had IC₅₀ values below 1 µM.

Potency at other beta adrenoreceptor subtypes was determined using chinese hamster ovary cells transfected with either the human beta 1 adrenoreceptor or the human beta 3 adrenoreceptor. Agonist activity was assessed by measuring changes in intracellular cyclic AMP.

The application of which this description and claims forms part may be used as a basis for priority in respect of any subsequent application. The claims of such subsequent application may be directed to any feature or combination of features described herein. They may take the form of product, composition, process, or use claims and may include, by way of example and without limitation, the following claims:

Claims

1. A compound of formula (I)



5

or a salt, solvate, or physiologically functional derivative thereof, wherein:

m is an integer of from 2 to 8;

10 n is an integer of from 3 to 11, preferably from 3 to 7;

with the proviso that m + n is 5 to 19, preferably from 5 to 12;

15 R¹ is -XNR⁶C(O)NR⁷R⁸; wherein

X is selected from -(CH₂)_p- and C₂₋₆alkenylene;


20 R⁶ and R⁸ are independently selected from hydrogen, C₁₋₆alkyl and C₃₋₇ cycloalkyl;

R⁷ is selected from hydrogen, C₁₋₆alkyl, C₃₋₇cycloalkyl, -C(O)R⁹, phenyl, naphthyl, hetaryl, and phenyl(C₁₋₄alkyl)- and R⁷ is optionally substituted by 1 or 2 groups independently selected from halo, hydroxy, C₁₋₆alkyl, C₁₋₆haloalkyl, C₁₋₆ alkoxy, -NHC(O)(C₁₋₆alkyl), -SO₂(C₁₋₆alkyl), -SO₂(phenyl), -CO₂H, and -CO₂(C₁₋₄alkyl);

25 R⁹ is selected from C₁₋₆alkyl, C₃₋₇cycloalkyl, -CO₂H, CO₂(C₁₋₄alkyl), phenyl, naphthyl, hetaryl, and phenyl(C₁₋₄alkyl)- and R⁹ is optionally substituted by 1 or 2 groups independently selected from halo, C₁₋₆alkyl, C₁₋₆haloalkyl, C₁₋₆ alkoxy, -NHC(O)(C₁₋₆alkyl), -SO₂(C₁₋₆alkyl), -SO₂(phenyl), -CO₂H, and -CO₂(C₁₋₄alkyl); and

30 p is an integer from 0 to 6, preferably from 0 to 4;

or R¹ is cyclised such that R⁸ forms a bond with the phenyl ring to which R¹ is attached, via the ring carbon atom adjacent to R¹, so as to form a moiety of the formula:



5

R² is selected from hydrogen, C₁₋₆alkyl, C₁₋₆alkoxy, phenyl, halo, and C₁₋₆haloalkyl;

R³ is selected from hydrogen, hydroxy, C₁₋₆alkyl, halo, C₁₋₆alkoxy, phenyl, C₁₋₆haloalkyl, and -SO₂NR¹⁰R¹¹;

10




wherein R¹⁰ and R¹¹ are independently selected from hydrogen, C₁₋₆alkyl, C₃₋₆cycloalkyl, phenyl, and phenyl (C₁₋₄alkyl), or R¹⁰ and R¹¹, together with the nitrogen to which they are bonded, form a 5-, 6-, or 7- membered nitrogen containing ring;

15 and R¹⁰ and R¹¹ are each optionally substituted by one or two groups selected from halo, C₁₋₆alkyl, and C₁₋₆haloalkyl;

R⁴ and R⁵ are independently selected from hydrogen and C₁₋₄alkyl with the proviso that the total number of carbon atoms in R⁴ and R⁵ is not more than 4;

20

and Ar¹ is a group selected from




(a)

(b)

(c)

and



(d)

wherein R¹² represents halogen, -(CH₂)_qOR¹⁶, -NR¹⁶C(O)R¹⁷, -NR¹⁶SO₂R¹⁷,
-SO₂NR¹⁶R¹⁷, -NR¹⁶R¹⁷, -OC(O)R¹⁸ or OC(O)NR¹⁶R¹⁷,

5 and R¹³ represents hydrogen, halogen or C₁₋₄ alkyl;

or R¹² represents -NHR¹⁹ and R¹³ and -NHR¹⁹ together form a 5- or 6- membered heterocyclic ring;

10 R¹⁴ represents hydrogen, halogen, -OR¹⁶ or -NR¹⁶R¹⁷;

R¹⁵ represents hydrogen, halogen, haloC₁₋₄ alkyl, -OR¹⁶, -NR¹⁶R¹⁷, -OC(O)R¹⁸ or OC(O)NR¹⁶R¹⁷;

15 R¹⁶ and R¹⁷ each independently represents hydrogen or C₁₋₄ alkyl, or in the groups -NR¹⁶R¹⁷, -SO₂NR¹⁶R¹⁷ and -OC(O)NR¹⁶R¹⁷, R¹⁶ and R¹⁷ independently represent hydrogen or C₁₋₄ alkyl or together with the nitrogen atom to which they are attached form a 5-, 6- or 7- membered nitrogen-containing ring,

20 R¹⁸ represents an aryl (eg phenyl or naphthyl) group which may be unsubstituted or substituted by one or more substituents selected from halogen, C₁₋₄ alkyl, hydroxy, C₁₋₄ alkoxy or halo C₁₋₄ alkyl; and


25 q is zero or an integer from 1 to 4;

with the provisos that:

- 5 c) when Ar¹ denotes a group (i) as defined herinafter, R², R³, R⁴, R⁵, and R⁶ each denote hydrogen, m is 5, n is 2, and X denotes -(CH₂)_p- and is in the para position relative to the -O-(CH₂)_n- link, and p is 0, then R⁷ and R⁸ are not both hydrogen; and
d) when Ar¹ denotes a group (i) as defined hereinafter, R², R³, R⁴, R⁵, and R⁶ each denote hydrogen, m is 5, n is 4, and X denotes -(CH₂)_p- and is in the para position relative to the -O-(CH₂)_n- link, and p is 0, then R⁷ and R⁸ are not both methyl;

2. A compound of formula (Ia)


10



or a salt, solvate, or physiologically functional derivative thereof, wherein R¹ and R³ are as defined above for formula (I).

15

3. A compound of formula (Ib)



20

or a salt, solvate, or physiologically functional derivative thereof, wherein R¹ is as defined above for formula (I).

25

4. A compound of formula (I) or (Ia) selected from:

N-[3-(4-{{(2R)-2-hydroxy-2-[4-hydroxy-3-(hydroxymethyl)phenyl]ethyl}amino}hexyl]oxy}butyl]phenyl]urea;
3-(4-{{[6-((2R)-2-hydroxy-2-[4-hydroxy-3-(hydroxymethyl)phenyl]ethyl)}-
amino}hexyl]oxy}butyl)phenyl)-N'-phenylurea;
5 N-[3-(4-{{[6-((2S)-2-hydroxy-2-[4-hydroxy-3-(hydroxymethyl)phenyl]ethyl)}-
amino}hexyl]oxy}butyl)phenyl]-N'-phenylurea;
3-(4-{{[6-((2S)-2-hydroxy-2-[4-hydroxy-3-(hydroxymethyl)phenyl]ethyl)}-
amino}hexyl]oxy}butyl)phenyl)-N'-phenylurea;
N-[3-(4-{{[2-hydroxy-2-[4-hydroxy-3-(hydroxymethyl)phenyl]ethyl}amino}hexyl]oxy}butyl]phenyl]urea;
10 3-(4-{{[6-((2R)-2-hydroxy-2-[4-hydroxy-3-(hydroxymethyl)phenyl]ethyl)}-
amino}hexyl]oxy}butyl)phenyl)-N'-phenylurea; and
N-[3-(4-{{[6-((2R)-2-hydroxy-2-[4-hydroxy-3-(hydroxymethyl)phenyl]ethyl}amino}hexyl]oxy}butyl)-5-methylphenyl]urea;

15

or a salt, solvate or physiologically functional equivalent thereof.

5. A method for the prophylaxis or treatment of a clinical condition in a mammal, such as a human, for which a selective β_2 -adrenoreceptor agonist is indicated, which 20 comprises administration of a therapeutically effective amount of a compound of formula (I), (Ia) or (Ib) according to any of claims 1 to 4, or a pharmaceutically acceptable salt, solvate, or physiologically functional derivative thereof.
- 25 6. A compound of formula (I), (Ia) or (Ib) according to any of claims 1 to 4 or a pharmaceutically acceptable salt, solvate, or physiologically functional derivative thereof for use in medical therapy.
- 30 7. A pharmaceutical formulation comprising a compound of formula (I), (Ia) or (Ib) according to any of claims 1 to 4 or a pharmaceutically acceptable salt, solvate, or physiologically functional derivative thereof, and a pharmaceutically acceptable carrier or excipient, and optionally one or more other therapeutic ingredients.
- 35 8. A combination comprising a compound of formula (I), (Ia) or (Ib) according to any of claims 1 to 4 or a pharmaceutically acceptable salt, solvate, or physiologically functional derivative thereof, and one or more other therapeutic ingredients.

9. A combination according to claim 8 wherein the other therapeutic ingredient is a corticosteroid, an anticholinergic or a PDE4 inhibitor.

5


10. The use of a compound of formula (I), (Ia) or (Ib) according to any of claims 1 to 4, or a pharmaceutically acceptable salt, solvate, or physiologically functional derivative thereof in the manufacture of a medicament for the prophylaxis or treatment of a clinical condition for which a selective β_2 -adrenoreceptor agonist is indicated.

10

11. A process for the preparation of a compound of formula (I), (Ia) or (Ib) according to any of claims 1 to 4, or a salt, solvate, or physiologically functional derivative thereof, which comprises:

15


(a) deprotection of a protected intermediate, for example of formula (II):



20 or a salt or solvate thereof, wherein R^1 , R^2 , R^3 , R^4 , R^5 , m , and n are as defined for the compound of formula (I), (Ia) or (Ib), Ar^{1a} represents an optionally protected form of Ar^1 ; and P^1 and P^2 are each independently either hydrogen or a protecting group, provided that the compound of formula (II) contains at least one protecting group.

(b) alkylation of an amine of formula (XII)


25



wherein Ar^{1a} is an optionally protected form of Ar^1 and P^2 is either hydrogen or a protecting group,


30

with a compound of formula (XIII):




5 wherein R^1 , R^2 , R^3 , R^4 , R^5 , m , and n are as defined for the compound of formula (I) or (Ia) and L^2 is a leaving group;

(c) reduction of a compound of formula (XIV):




10 wherein R^1 , R^2 , R^3 , R^4 , R^5 , m and n are as defined for formula (I), Ar^{1a} is an optionally protected form of Ar^1 , and P^1 and P^2 are each independently hydrogen or a protecting group as defined above;

15 (d) reacting a compound of formula (XVIII):




wherein Ar^{1a} is an optionally protected form of Ar^1 , and P^1 is hydrogen or a protecting group and L^4 is a leaving group as defined above for groups $\text{L}-\text{L}^3$ with an amine of formula (XIX):



wherein R¹, R², R³, R⁴, R⁵, R¹⁰, m and n are as defined for formula (II); or

- 5 (e) removal of a chiral auxiliary from a compound of formula (IIa):



- 10 wherein R¹ – R⁵, m and n are as defined for formula (I), Ar^{1a} and P¹ are as defined for formula (II) each independently represent hydrogen or a protecting group and R²⁷ represents a chiral auxiliary.


followed by the following steps in any order:

- 15 (i) optional removal of any protecting groups;
 (ii) optional separation of an enantiomer from a mixture of enantiomers;
 (iii) optional conversion of the product to a corresponding salt, solvate, or physiologically functional derivative thereof.

ABSTRACT

The present invention relates to novel compounds of formula (I),

5



to a process for their manufacture, to pharmaceutical compositions containing them,
10 and to their use in therapy, in particular their use in the prophylaxis and treatment of
respiratory diseases.

10

PCT Application

EP0312161

